

Initial REMS Approval: 10/2011
Last modified/revised: 10/2016

BLA 125104

TYSABRI® (natalizumab) Intravenous Injection

Monoclonal Antibody

**Biogen, Inc
14 Cambridge Center
Cambridge, MA 02142**

(617) 679-2000

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

**TYSABRI Outreach: Unified Commitment to Health (TOUCH®) Prescribing
Program (MS & CD)**

I. GOALS:

The goals of the TYSABRI REMS are:

1. To inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with longer treatment duration, prior immunosuppressant use and the presence of anti-JCV antibodies.
2. To warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents, and in patients who are immunocompromised.
3. To promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML.

II. REMS ELEMENTS:

A. Medication Guide

A Medication Guide (MG) for TYSABRI will be dispensed to each patient prior to each TYSABRI infusion in accordance with 21 CFR 208.24.

Please see the appended Medication Guide.

B. Elements to Assure Safe Use

1. Healthcare providers who prescribe TYSABRI are specially certified.

- A. Biogen will ensure that health care providers who prescribe TYSABRI are specially certified.
- B. To become certified, prescribers will be required to enroll in the TOUCH® Prescribing Program by completing the following requirements:
 - i. Review the TYSABRI REMS prescriber educational materials, including the full Prescribing Information.
 - ii. Complete and sign the Prescriber/Patient Enrollment Form and acknowledge the following:
 - a) I have read and understand the full Prescribing Information for TYSABRI
 - b) I understand that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. When initiating and continuing treatment with

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

TYSABRI, I should consider whether the expected benefit of TYSABRI is sufficient to offset this risk

- c) I am aware that cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI monotherapy
- d) I understand that three risk factors identified thus far that increase the risk of PML in TYSABRI-treated patients are:

- Longer treatment duration, especially beyond 2 years
- Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil)
- The presence of anti-JCV antibodies.

These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI.

- e) I understand that MRI findings may be apparent before clinical signs or symptoms. Periodic monitoring for radiographic signs consistent with PML should be considered to allow for an early diagnosis of PML. Lower PML-related mortality and morbidity have been reported following TYSABRI discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis.
- f) To my knowledge, this patient has no known contraindications to TYSABRI, including PML
- g) I have instructed this patient to promptly report to me any new or worsening symptoms that persist over several days, especially nervous system symptoms
- h) I understand that this patient should be seen and evaluated 3 months after the first infusion, 6 months after the first infusion, every 6 months thereafter for as long as this patient receives TYSABRI, and for at least 6 months after TYSABRI has been discontinued
- i) I will determine every 6 months whether this patient should continue on TYSABRI and, if so, authorize treatment for another 6 months
- j) I understand that I am required to submit an “Initial Discontinuation Questionnaire” when TYSABRI is discontinued and a “6-Month Discontinuation Questionnaire” following discontinuation of TYSABRI.

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- k) I should report to Biogen, as soon as possible, cases of PML, hospitalizations due to opportunistic infection, or deaths
- l) I understand that data concerning this patient and me will be entered into the mandatory TOUCH Prescribing Program. Biogen requires my cooperation with periodic data collection. Failure to provide the requested information or otherwise comply with the requirements of the TOUCH Prescribing Program may result in discontinuation of TYSABRI treatment for this patient and termination of my authorization to prescribe TYSABRI
- m) I have received educational materials regarding the benefits and risks of TYSABRI treatment
- n) I have, or another healthcare provider under my direction has, educated this patient on the benefits and risks of treatment with TYSABRI, provided him or her with the Patient Medication Guide and Enrollment Form, instructed him or her to read these materials, and encouraged him or her to ask questions when considering TYSABRI

Acknowledgments specific to Multiple Sclerosis (MS)

- o) I understand that TYSABRI is indicated as monotherapy for relapsing forms of MS
- p) I understand that this patient has a relapsing form of MS based on clinical and radiological evidence
- q) I understand that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. When initiating and continuing treatment with TYSABRI, I should consider whether the expected benefit of TYSABRI is sufficient to offset this risk
- r) I understand that TYSABRI is not ordinarily recommended for patients who are receiving chronic immunosuppressant or immunomodulatory therapy, or who are significantly immunocompromised from any other cause
- s) I understand that an MRI should be performed prior to initiating therapy with TYSABRI in MS patients

Acknowledgments specific to Crohn's Disease (CD)

- t) I understand that TYSABRI is indicated for adult patients with moderately to severely active CD with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF - α

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- u) I understand that patients receiving TYSABRI should not take concomitant immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF- α
- v) I understand that this patient has moderately to severely active CD with evidence of inflammation
- w) I have discussed other Crohn's disease treatments with this patient
- x) I understand that TYSABRI should be discontinued if a patient has not experienced a therapeutic benefit by 12 weeks of therapy
- y) I understand that patients receiving steroid therapy at the time of TYSABRI initiation must undergo a steroid tapering regimen once a therapeutic response is achieved. If the patient with Crohn's disease cannot be tapered off of steroids within six months of starting TYSABRI, TYSABRI should be discontinued

C. Biogen will:

- i. Ensure that prescriber enrollment can successfully be completed
- ii. Ensure that prescribers receive the TYSABRI prescribing information and the following materials that are part of the TYSABRI REMS and are appended:
 - TOUCH Prescribing Program Educational Slide Set
 - TOUCH Prescribing Program Enrollment Kits (specific to MS or CD)
 - TOUCH Prescribing Program Overview
 - Medication Guide
 - Prescriber/Patient Enrollment Form (MS or CD)
 - Pre-Infusion Patient Checklist (combined MS and CD)
 - Helpful Information for Evaluation of New Neurologic Symptoms in Patients Receiving TYSABRI (MS)
 - Understanding PML for Gastroenterologists (CD)
 - TOUCH On-Line (www.TOUCHPROGRAM.com)
 - Change Prescriber Authorization Form
 - 12 Week Questionnaire for Crohn's Disease
 - Patient Status Report and Reauthorization Questionnaire (specific to MS and CD)

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- Initial Discontinuation Questionnaire (specific to MS or CD)
- 6-Month Discontinuation Questionnaire (specific to MS or CD)
- iii. Ensure that enrollment forms are complete before activating a prescriber's enrollment in the TOUCH Prescribing Program.
- iv. Ensure that prescribers are notified when they are successfully enrolled in the TOUCH Prescribing Program, and therefore, are certified to prescribe TYSABRI.

2. TYSABRI will be dispensed only by pharmacies and infusion sites that are specially certified.

- a. Biogen will ensure that certified pharmacies that dispense TYSABRI are specially certified.
- b. Pharmacies that dispense TYSABRI to infusion sites must enroll in the Tysabri TOUCH Prescribing Program by submitting a completed enrollment form and designating a person with appropriate authority to acknowledge the following:
 - i. The pharmacy has received training and educational materials on the TOUCH Prescribing Program
 - ii. I understand that certified pharmacies may dispense TYSABRI only to authorized infusion sites
 - iii. I understand that, per the requirements of the TOUCH Prescribing Program, this certified pharmacy's compliance may be reviewed by the Food and Drug Administration (FDA) and/or audited by Biogen and/or a third party designated by Biogen.
 - iv. I understand that noncompliance with the requirements of the TOUCH Prescribing Program may result in my pharmacy no longer being enrolled and termination of our participation in the program.
- c. Biogen will:
 - i. Ensure that pharmacies are notified when they are successfully enrolled in the TOUCH Prescribing Program, and therefore, are certified to dispense TYSABRI.
 - ii. Ensure the pharmacies that dispense TYSABRI to authorized infusion sites have been trained on the known risks, potential benefits, and appropriate use of TYSABRI using approved educational materials
- d. The following materials are part of the TYSABRI REMS and are appended:
 - TOUCH Prescribing Program Educational Slide Set

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- TOUCH Prescribing Program Overview
 - Certified Pharmacy Enrollment Form
- e. Biogen will ensure that infusion sites where TYSABRI is dispensed and administered are specially certified.
- i. Infusion sites that dispense and administer TYSABRI must enroll in the TOUCH Prescribing Program by submitting a completed Infusion Site Enrollment Form and designating a person with appropriate authority to acknowledge the following:
- a) The infusion site has received training and educational materials on the TOUCH Prescribing Program
 - b) I understand that TYSABRI will be administered only to patients who are currently authorized in the TOUCH Prescribing Program. Patient authorization must be confirmed *prior to each infusion* by:
 - 1) For TOUCH On-Line infusion sites: Patient Authorization Status must be “Authorized” or
 - 2) For paper-based infusion sites: Receipt of current Notice of Patient Authorization and verification that no Notice of Patient Discontinuation is on file
 - c) I understand that each patient will receive a copy of the TYSABRI Patient Medication Guide *prior to each infusion*
 - d) I understand that a TYSABRI Pre-infusion Patient Checklist must be completed *prior to each infusion*. The Pre-infusion Patient Checklist must be submitted to Biogen within 1 business day of the patient visit, regardless of whether or not the patient received the infusion, by:
 - 1) For paper-based infusion sites: sending a copy of the completed Pre-infusion Patient Checklist to Biogen. A copy must also be placed in the patient’s medical record
 - 2) For TOUCH On-Line infusion sites: The infusion nurse can read, complete and submit the Pre-Infusion Patient Checklist directly in TOUCH On-Line
 - e) I understand that, per the requirements of the TOUCH Prescribing Program, this infusion site’s compliance with the REMS may be reviewed by FDA and/or audited by Biogen and/or a third party designated by Biogen.
 - f) I understand that noncompliance with the requirements of the TOUCH Prescribing Program will result in de-enrollment of the infusion site.
- f. Biogen will:

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- i. Ensure that infusion sites are notified when they are successfully enrolled in the TYSABRI REMS Program, and therefore, are certified to dispense and administer TYSABRI.
 - ii. Ensure that infusion sites that dispense and administer TYSABRI have been trained on the known risks, potential benefits, and appropriate use of TYSABRI using approved educational materials.
- g. The following materials are a part of the TYSABRI REMS and are appended:
- TOUCH Prescribing Program Educational Slide Set
 - TOUCH Prescribing Program Overview
 - Infusion Site Enrollment Form
 - Pre-Infusion Patient Checklist
 - Medication Guide

3. TYSABRI will be dispensed to patients with evidence or other documentation of safe-use conditions.

- a. Biogen will ensure that certified prescribers enroll all patients into the TOUCH Prescribing Program by completing the Prescriber/Patient Enrollment Form for each new patient.
- b. A completed and signed Prescriber/Patient Enrollment Form must be submitted to Biogen before the patient may receive an infusion.

The Prescriber/Patient Enrollment Form requires the patient to acknowledge the following:

- i. I understand that TYSABRI increases my chance of getting a rare brain infection that usually leads to death or severe disability
 - a) This infection is called progressive multifocal leukoencephalopathy (PML). PML usually happens in people with weakened immune systems
 - b) There is no known treatment, prevention, or cure for PML
 - c) I should call my doctor right away if I get any new or worsening symptoms that last several days, especially nervous system symptoms, while I am taking TYSABRI, and for at least 6 months after I stop taking TYSABRI. Some of these symptoms include a new or sudden change in my thinking, eyesight, balance, or strength, but I should also report other new or worsening symptoms
 - d) My chance for getting PML increases if I:

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

- 1) Have received TYSABRI for a long time especially longer than 2 years
- 2) Have received certain medicines that can weaken my immune system before I start receiving TYSABRI
- 3) Have been exposed to John Cunningham Virus (JCV). JCV is a common virus that is harmless in most people but can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Most people who are exposed to JCV do not know it or have any symptoms. This exposure usually happens in childhood. My doctor may do a blood test to check if I have been exposed to JCV before I start receiving TYSABRI or during my treatment

My risk of getting PML is greatest if I have all 3 risk factors listed above. There may be other risk factors for getting PML during TYSABRI treatment that we do not know about yet. My doctor should discuss the risks and benefits of TYSABRI treatment with me before I decide to receive TYSABRI.

ii. Acknowledgments specific to MS

I understand that TYSABRI is a medicine approved to treat patients with relapsing forms of multiple sclerosis (MS)

- a) TYSABRI increases the risk of PML. I understand that when starting and continuing treatment with TYSABRI, I should talk to my doctor about whether the expected benefit of TYSABRI is enough to outweigh this risk (see important information about PML below)
- b) I have talked to my doctor and understand the benefits and risks of TYSABRI treatment
- c) My chance for getting PML may be higher if I am also being treated with other medicines that can weaken my immune system, including other MS treatments. Even if I use TYSABRI alone to treat my MS, I can still get PML

iii. Acknowledgments specific to CD

I understand that TYSABRI is a medicine approved to treat patients with moderate to severe Crohn's Disease who have not been helped enough by, or cannot tolerate, usual Crohn's disease medicines and medicines called tumor necrosis factor (TNF) inhibitors

- a) I have talked to my doctor and understand the benefits and risks of TYSABRI treatment
- b) I understand that I should not take certain medicines that weaken the immune system while I am taking TYSABRI
- c) My chance for getting PML may be higher if I am also being treated with other medicines that can weaken my immune system, including other Crohn's disease

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

treatments. Even if I use TYSABRI alone to treat my Crohn's disease, I can still get PML.

- c. To receive TYSABRI all patients must be enrolled in a special program called the TOUCH Prescribing Program.
 - i. The TOUCH Prescribing Program is run by the company that makes TYSABRI. Under this program, the company is required to collect information about my health at regular time periods. I cannot receive TYSABRI if I do not agree to follow the requirements of the TOUCH Prescribing Program
 - ii. The company may use my information to meet the requirements of the TOUCH Prescribing Program, including helping me locate an authorized infusion site
 - iii. I must notify the TOUCH Prescribing Program if I switch physicians or infusion sites
 - iv. I have received, read, and understand the Patient Medication Guide
 - v. I will bring to each TYSABRI infusion a list of all medicines and treatments that I have taken during the last month

The following materials are part of the TYSABRI REMS and are appended:

- Prescriber/Patient Enrollment Forms (specific to MS or CD)
- Medication Guide

Biogen will make these materials available for the enrolled prescribers to provide to their patients.

C. Implementation System

The Implementation system for the TYSABRI REMS includes the following:

- a. Biogen must maintain a secure, validated database of all certified prescribers, certified pharmacies, certified infusion sites, and enrolled patients in the TOUCH Prescribing Program. The TOUCH Prescribing Program is an integrated, computerized, validated database that captures enrollment, patient tracking, and drug distribution data.
- b. Biogen will monitor the distribution of TYSABRI to ensure that the drug is only delivered to certified pharmacies and infused by certified infusion sites.
- c. Biogen will monitor the compliance of certified entities (i.e. pharmacies, infusion sites, and prescribers) as acknowledged in the signed entity specific enrollment form and, if appropriate, institute corrective actions, which could include retraining and de-enrollment
- d. Biogen will maintain TOUCH On-Line, which is an internet-based system that will allow enrolled TOUCH Prescribing Program participants the option of real-time access to view

Initial REMS Approval: 10/2011

Last modified/revised: 10/2016

and/or submit required or pertinent patient therapy information collected through the TOUCH Prescribing Program, such as information on the Pre-infusion Patient Checklist, the TYSABRI Patient Status Report and Reauthorization Questionnaire, and the TYSABRI Patient Discontinuation Questionnaire.

- e. Biogen will monitor and evaluate the implementation of the elements to assure safe use and take reasonable steps to work to improve implementation of these elements.

D. Timetable for Submission of Assessments of the REMS

Biogen will submit REMS Assessments annually from the date of the initial approval of the REMS (October 7, 2011). To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Biogen will submit each assessment so that it will be received by the FDA on or before the due date.

MEDICATION GUIDE
TYSABRI® (tie-SA-bree)
(natalizumab) injection, for intravenous use

Read this Medication Guide before you start receiving **TYSABRI** and before you receive each dose. There may be new information. This Medication Guide does not take the place of talking to your doctor about your medical condition or your treatment.

What is the most important information I should know about **TYSABRI?**

- **TYSABRI increases your chance (risk) of getting a rare brain infection that usually leads to death or severe disability. This infection is called progressive multifocal leukoencephalopathy (PML). If PML happens, it usually happens in people with weakened immune systems.**
 - There is no known treatment, prevention, or cure for PML.
 - Your chance of getting PML may be higher if you are also being treated with other medicines that can weaken your immune system, including other treatments for **Multiple Sclerosis (MS)** and **Crohn's disease (CD)**. You should not take certain medicines that weaken your immune system at the same time you are taking **TYSABRI**. Even if you use **TYSABRI** alone to treat your **MS** or **CD**, you can still get PML.
 - Your risk of getting PML is higher if you:
 - have received **TYSABRI** for a long time, especially longer than 2 years
 - have received certain medicines that can weaken your immune system before you start receiving **TYSABRI**
 - have been infected by the John Cunningham Virus (JCV). JCV is a common virus that is harmless in most people but can cause PML in people who have weakened immune systems, such as people taking **TYSABRI**. Most people who are infected by JCV do not know it or do not have any symptoms. This infection usually happens in childhood. Before you start receiving **TYSABRI** or during your treatment, your doctor may do a blood test to check if you have been infected by JCV.
- Your risk of getting PML is greatest if you have all 3 risk factors listed above. There may be other risk factors for getting PML during **TYSABRI** treatment that we do not know about yet. Your doctor should discuss the risks and benefits of **TYSABRI** treatment with you before you decide to receive **TYSABRI**. See “What are the possible side effects of **TYSABRI**?”**
- While you receive **TYSABRI**, and for 6 months after you stop receiving **TYSABRI**, it is important that you call your doctor right away if you have any new or worsening medical problems that have lasted several days. These may be new or sudden and include problems with:
 - thinking
 - eyesight
 - strength
 - balance
 - weakness on 1 side of your body
 - using your arms and legs

Tell all your doctors that you are receiving **TYSABRI**.

- **Because of your risk of getting PML while you receive **TYSABRI**, **TYSABRI** is available only through a restricted distribution program called the **TOUCH® Prescribing Program**. To receive **TYSABRI**, you must talk to your doctor and understand the risks and benefits of **TYSABRI** and agree to follow all of the instructions in the **TOUCH® Prescribing Program**.**
- ****TYSABRI** is only:**
 - prescribed by doctors who are enrolled in the **TOUCH® Prescribing Program**
 - given at an infusion center that is enrolled in the **TOUCH® Prescribing Program**
 - given to people who are enrolled in the **TOUCH® Prescribing Program**
- **Before you receive **TYSABRI**, your doctor will:**
 - explain the **TOUCH® Prescribing Program** to you
 - have you sign the **TOUCH® Prescriber and Patient Enrollment Form**

What is **TYSABRI?**

TYSABRI is a prescription medicine used to treat adults with:

- relapsing forms of Multiple Sclerosis (MS). **TYSABRI** can:
 - slow the worsening of symptoms common in people with MS
 - decrease the number of flare-ups (relapses)
- TYSABRI** increases the risk of PML. When starting and continuing treatment with **TYSABRI**, it is important that you discuss with your doctor whether the expected benefit of **TYSABRI** is enough to outweigh this risk. See “**What is the most important information I should know about **TYSABRI**?**”
- moderate to severe Crohn's disease (CD). **TYSABRI** is used:
 - to reduce signs and symptoms of CD
 - in people who have not been helped enough by, or cannot use the usual CD medicines and medicines called tumor necrosis factor (TNF) inhibitors.
 - It is not known if people older than 65 years of age respond differently to **TYSABRI**.
 - It is not known if **TYSABRI** is safe and effective in children under 18 years of age.

Who should not receive **TYSABRI?**

Do not receive **TYSABRI if you:**

- have PML
- are allergic to natalizumab or any of the ingredients in **TYSABRI**. See the end of this Medication Guide for a complete list of ingredients in **TYSABRI**.

Talk to your doctor before receiving **TYSABRI** if you have any of these conditions.

What should I tell my doctor before receiving each dose of TYSABRI?

Before you receive TYSABRI, tell your doctor if you:

- have medical conditions that can weaken your immune system, including:
 - HIV infection or AIDS
 - leukemia or lymphoma
 - an organ transplant
 - other medical conditions that can weaken your immune system
- have any new or worsening medical problems that have lasted several days. These may be new or sudden and include problems with:
 - thinking
 - eyesight
 - balance
 - strength
 - weakness on 1 side of your body
 - using your arms and legs
- have had hives, itching or trouble breathing during or after receiving a dose of TYSABRI
- have a fever or infection (including shingles or any unusually long lasting infection)
- are pregnant or plan to become pregnant. It is not known if TYSABRI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. TYSABRI can pass into your breast milk. It is not known if the TYSABRI that passes into your breast milk can harm your baby. Talk to your doctor about the best way to feed your baby while you receive TYSABRI.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Especially tell your doctor if you take medicines that can weaken your immune system. Ask your doctor if you are not sure.

Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.

How should I receive TYSABRI?

- TYSABRI is given 1 time every 4 weeks through a needle placed in your vein (IV infusion).
- Before each TYSABRI dose you will be asked questions to make sure TYSABRI is still right for you.

What are the possible side effects of TYSABRI?

TYSABRI may cause serious side effects, including:

- **See “What is the most important information I should know about TYSABRI?”**
- **Herpes Encephalitis and Meningitis.** TYSABRI may increase your risk of getting an infection of the brain or the covering of your brain and spinal cord (encephalitis or meningitis) caused by herpes viruses that may lead to death. Call your doctor right away if you have sudden fever, severe headache, or if you feel confused after receiving TYSABRI.
- **Liver damage.** Symptoms of liver damage can include:
 - yellowing of the skin and eyes (jaundice)
 - nausea
 - vomiting
 - unusual darkening of the urine
 - feeling tired or weakCall your doctor right away if you have symptoms of liver damage. Your doctor can do blood tests to check for liver damage.
- **Allergic reactions, including serious allergic reactions.** Symptoms of an allergic reaction can include:
 - hives
 - itching
 - trouble breathing
 - chest pain
 - dizziness
 - wheezing
 - chills
 - rash
 - nausea
 - flushing of skin
 - low blood pressureSerious allergic reactions usually happen within 2 hours of the start of your infusion, but they can happen at any time after you receive TYSABRI. Tell your doctor right away if you have any symptom of an allergic reaction, even if it happens after you leave the infusion center. You may need treatment if you are having an allergic reaction.
- **Infections.** TYSABRI may increase your chance of getting an unusual or serious infection because TYSABRI can weaken your immune system. You have a higher risk of getting infections if you also take other medicines that can weaken your immune system.

The most common side effects of TYSABRI include:

- headache
- feeling tired
- urinary tract infection
- joint pain
- lung infection
- depression
- pain in your arm and legs
- diarrhea
- vaginitis
- rash
- nose and throat infections
- nausea
- stomach area pain

Tell your doctor about any side effect that bothers you or that does not go away.

These are not all the possible side effects of TYSABRI. Ask your doctor for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of TYSABRI.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide.

This Medication Guide summarizes the most important information about TYSABRI. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about TYSABRI that is written for healthcare professionals.

For more information, go to www.TYSABRI.com or call 1-800-456-2255.

What are the ingredients in TYSABRI?

Active ingredient: natalizumab

Inactive Ingredients: sodium chloride, sodium phosphate, monobasic, monohydrate; sodium phosphate, dibasic, heptahydrate; polysorbate 80, and water for injection

Manufactured by: Biogen Inc.; Cambridge, MA 02142 USA



Touch[®] PRESCRIBING PROGRAM
TYSABRI Outreach: Unified Commitment to Health

Please see full Prescribing Information, including Boxed Warning, for important safety information.

TYSABRI[®]
(natalizumab)

Objectives

- Provide an overview of important safety information
- Provide an overview of the TOUCH Prescribing Program for Multiple Sclerosis (MS) and Crohn's disease (CD)
- Review the process steps to complete TOUCH Prescribing Program components including use of TOUCH On-Line
- Review specific MS TOUCH and/or CD TOUCH Prescribing Program materials
- Review the responsibilities of each participant in the TOUCH Prescribing Program

Indications and Usage – Multiple Sclerosis

- TYSABRI® (natalizumab) is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis.
- TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML).
- When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk.
- See Full Prescribing Information regarding the risk of PML with TYSABRI.

Indications and Usage – Crohn's Disease

- TYSABRI® is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF- α .
- TYSABRI should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF- α .

BOXED WARNING

- TYSABRI® increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability.
- Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI.
- Healthcare professionals should monitor patients on TYSABRI® for any new sign or symptom that may be suggestive of PML.
- TYSABRI dosing should be withheld immediately at the first sign or symptom that may be suggestive of PML.

BOXED WARNING

- For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.
- Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program.

Contraindications

- TYSABRI is contraindicated in patients who have or have had PML.
- TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI.

Warnings and Precautions - PML

- Three factors that are known to increase the risk of PML in TYSABRI-treated patients have been identified:
 - Longer treatment duration, especially beyond 2 years. There is limited experience in patients who have received more than 6 years of TYSABRI treatment
 - Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil)
 - The presence of anti-JCV antibodies. Patients who are anti-JCV antibody positive have a higher risk for developing PML
- These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI.

Warnings and Precautions – PML

- Infection by the JC virus (JCV) is required for the development of PML.
- Anti-JCV antibody testing should not be used to diagnose PML.
- Anti-JCV antibody negative status indicates that exposure to the JC virus has not been detected.
- Patients who are anti-JCV antibody negative have a lower risk of PML than those who are positive. Patients who are anti-JCV antibody negative are still at risk for the development of PML due to the potential for a new JCV infection, or a false negative test result.

Warnings and Precautions – PML

- MRI findings may be apparent before clinical signs or symptoms suggestive of PML.
- Periodic monitoring for radiographic signs consistent with PML should be considered to allow for an early diagnosis of PML.
- Lower PML-related mortality and morbidity have been reported following TYSABRI discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis.

Warnings and Precautions – PML

- The reported rate of seroconversion in patients with MS (changing from anti-JCV antibody negative to positive) is 3 to 8 percent annually. In addition, some patients' serostatus may change intermittently. Therefore, patients with a negative anti-JCV antibody test result should be retested periodically.
- For purposes of risk assessment, a patient with a positive anti-JCV antibody test at any time is considered anti-JCV antibody positive regardless of the results of any prior or subsequent anti-JCV antibody testing. When assessed, anti-JCV antibody status should be determined using an analytically and clinically validated immunoassay.
- Anti-JCV antibody testing should not be performed for at least two weeks following plasma exchange due to the removal of antibodies from the serum.

Warnings and Precautions – Herpes Encephalitis and Meningitis

- TYSABRI increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses.
- Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving TYSABRI.
- Monitor patients receiving TYSABRI for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, TYSABRI should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.

Warnings and Precautions – Hepatotoxicity

- Clinically significant liver injury, including acute liver failure requiring transplant, has been reported in patients treated with TYSABRI® in a postmarketing setting.
- Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurred as early as 6 days after the first dose; and signs of liver injury have also been reported for the first time after multiple doses.
- In some patients, liver injury recurred upon rechallenge, providing evidence that TYSABRI caused the injury.
- The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients.
- TYSABRI should be discontinued in patients with jaundice or other evidence of significant liver injury (e.g., laboratory evidence).

Warnings and Precautions – Hypersensitivity/Antibody Formation

- TYSABRI has been associated with hypersensitivity reactions, including serious systemic reactions (e.g., anaphylaxis), which occurred at an incidence of <1%.
- Patients who receive TYSABRI after an extended period without treatment may be at higher risk of hypersensitivity reactions.
- If a hypersensitivity reaction occurs, discontinue the use of TYSABRI, and initiate appropriate therapy.
- Do not re-treat with TYSABRI.
- Patients who receive TYSABRI for a short exposure (1 to 2 infusions) followed by an extended period without treatment are at higher risk of developing anti-natalizumab antibodies and/or hypersensitivity reactions on re-exposure, compared to patients who received regularly scheduled treatment.

Warnings and Precautions – Immunosuppression/Infections

- The immune system effects of TYSABRI® may increase the risk for infections.
- Concurrent use of antineoplastic, immunosuppressant, or immunomodulating agents may further increase the risk of infections, including PML and other opportunistic infections, over the risk observed with use of TYSABRI alone.
- The safety and efficacy of TYSABRI in combination with antineoplastic, immunosuppressant, or immunomodulating agents have not been established.
- For patients with Crohn's disease who start TYSABRI while on chronic corticosteroids, commence steroid withdrawal as soon as a therapeutic benefit has occurred. If the patient cannot discontinue systemic corticosteroids within 6 months, discontinue TYSABRI.

Adverse Reactions

- The most frequently reported serious adverse reactions in the Study MS1 were infections (3.2% vs 2.6% placebo), acute hypersensitivity reactions (1.1% vs 0.3%), depression (1.0% vs 1.0%), and cholelithiasis (1.0% vs 0.3%).
- The following serious adverse events in the induction Studies CD1 and CD2 were reported more commonly with TYSABRI than placebo and occurred at an incidence of at least 0.3%: intestinal obstruction or stenosis (2% vs. 1% in placebo), acute hypersensitivity reactions (0.5% vs. 0%), abdominal adhesions (0.3% vs. 0%), and cholelithiasis (0.3% vs. 0%).

Adverse Reactions (cont'd)

- The most common adverse reactions reported at an incidence of >10% were headache (38% vs 33%), fatigue (27% vs 21%), infusion reactions (24% vs 18%), urinary tract infections (21% vs 17%), arthralgia (19% vs 14%), depression (19% vs 16%), lower respiratory tract infection (17% vs 16%), pain in extremity (16% vs 14%), rash (12% vs 9%), gastroenteritis (11% vs 9%), abdominal discomfort (11% vs 10%), vaginitis* (10% vs 6%), and diarrhea (10% vs 9%).

*Percentage based on female patients only.

- Other common adverse reactions (incidence 10%) in the CD population were upper respiratory tract infections and nausea.
- Based on animal data, TYSABRI may cause fetal harm. TYSABRI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Program Overview

- **What is the TOUCH Prescribing Program?**
- What tools support the TOUCH Prescribing Program?
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- What is the enrollment process?
- What is the process to infuse TYSABRI®?
- How are patients tracked?
- What is TOUCH On-Line?

What is the TOUCH Prescribing Program?




A program that makes TYSABRI® available only to prescribers, infusion centers, pharmacies associated with infusion centers, and patients who are enrolled in the program

What is the TOUCH Prescribing Program designed to do?


- To inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI® including the increased risk of PML with longer treatment duration, prior immunosuppressant use, and the presence of anti-JCV antibodies
- To warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised
- To promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML

What are the program requirements?



TOUCH Prescribing Program Components

There are 3 main components of the TOUCH Prescribing Program




NOTE: This overview of the TOUCH Prescribing Program components does not include a complete list of the program requirements.

Program Overview


- What is the TOUCH Prescribing Program?
- **What tools support the TOUCH Prescribing Program?**
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- What is the enrollment process?
- What is the process to infuse TYSABRI®?
- How are patients tracked?
- What is TOUCH On-Line?

Tools to Support the TOUCH Prescribing Program – MS


Enrollment Forms



Prescriber/Patient



Infusion Site




Certified Pharmacy




Patient Medication Guide




Notice of Patient Authorization



Pre-infusion Patient Checklist



Helpful Information for Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI®



TOUCH Prescribing Program Overview

Tools to Support the TOUCH Prescribing Program – Crohn's Disease

Enrollment Forms



Prescriber/Patient



Infusion Site




Certified Pharmacy




Patient Medication Guide




Notice of Patient Authorization



Pre-infusion Patient Checklist



Understanding PML for Gastroenterologists



TOUCH Prescribing Program Overview



How Do I Communicate With TOUCH?



WEB

Touch On-Line
www.touchprogram.com



PHONE

1-800-456-2255

Monday – Friday



PAPER

Fax: 1-800-840-1278


Satisfying TOUCH Prescribing Program Requirements

- The TOUCH Prescribing Program has been designed to facilitate appropriate use of TYSABRI®
- In order to assess if the Program is meeting its goals, registered sites and enrolled participant's compliance may be reviewed by the FDA, and/or audited by Biogen and/or a third party designated by Biogen
- Compliance with the requirements of the TOUCH Prescribing Program is necessary to maintain authorization to prescribe, dispense, infuse, or receive TYSABRI. Failure to comply with these requirements may result in de-enrollment from the TOUCH Prescribing Program and termination of such authorization



Program Overview

- What is the TOUCH Prescribing Program?
- What tools support the TOUCH Prescribing Program?
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- **What is the enrollment process?**
- What is the process to infuse TYSABRI®?
- How are patients tracked?
- What is TOUCH On-Line?


Prescriber/Patient Enrollment



How do prescribers and patients enroll?



Enrollment Tools




Helpful Information for Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI®

Brochure provided by Biogen
Resource for: Neurology specialists


Key topics include:

- Importance of careful evaluation of any new or recurrent symptoms
- Differentiating between the signs, symptoms, and lesion characteristics typical of MS and PML
- PML diagnostic algorithm incorporating MRI and CSF assessment
- Action steps if PML is suspected
- Guidance on the treatment of relapse and other neurological symptoms



The information provided in this brochure is an educational resource and is not intended to be a substitute for consultation and review of relevant reference materials and medical literature. Treatment decisions should be made based on the context of the situation and clinical judgment.

Enrollment Tools




Understanding PML

Flashcard provided by Biogen

Resource for: Gastroenterologists, Internists, or other non-Neurology specialists


Key topics include:

- Characteristics of PML
- Guidance on recognizing PML in context of Crohn's disease
- Action steps if PML is suspected




The information provided in this brochure is an educational resource and is not intended to be a substitute for consultation and review of relevant reference materials and medical literature. Treatment decisions should be made based on the context of the situation and clinical judgment.

Infusion Site Enrollment



How does an Infusion Site enroll?



A Bigen representative provides mandatory indication-specific TOUCH Prescribing Program training to Infusion Site*




Infusion Site completes and faxes the **Infusion Site Enrollment Form** to TOUCH Prescribing Program

TOUCH Prescribing Program confirms that all paperwork is complete, assigns a **Site Authorization Number**, and faxes and mails the **Site Authorization Confirmation** to the Infusion Site




* NOTE: Infusion Sites must select to receive training and education materials on MS TOUCH, CD TOUCH, or both.

A patient will be matched **ONLY** with Infusion Sites that have been trained on the program materials related to his/her indication.



Certified Pharmacy Enrollment



How does a Certified Pharmacy* enroll?

A Biogen representative provides training to the **Certified Pharmacy** regarding the TOUCH Prescribing Program



The image shows a 'Certified Pharmacy Enrollment Form' from the TOUCH Prescribing Program. It includes fields for pharmacy name, address, phone, and fax, along with checkboxes for various program requirements. The form is branded with Biogen and TYSABRI logos.



The image shows a 'Certified Pharmacy Authorization Confirmation' form, labeled as 'IMPORTANT' and 'RETAIN FOR YOUR RECORDS'. It contains fields for pharmacy name, address, and phone, and includes a section for the pharmacy to sign and date. The form is branded with Biogen and TYSABRI logos.



Certified Pharmacy completes and faxes the **Certified Pharmacy Enrollment Form** to TOUCH Prescribing Program.



TOUCH Prescribing Program confirms that all paperwork is complete, assigns a **Site Authorization Number**, and faxes and mails the **Site Authorization Confirmation** to the Certified Pharmacy.




*A Certified Pharmacy is located within a hospital, group practice, or infusion site and is associated with an infusion site.


Program Overview

- What is the TOUCH Prescribing Program?
- What tools support the TOUCH Prescribing Program?
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- What is the enrollment process?
- **What is the process to infuse TYSABRI®?**
- How are patients tracked?
- What is TOUCH On-Line?

Infusion Overview



What process must be completed in order to infuse TYSABRI®?



TYSABRI should NOT be prepared until the **Pre-infusion Patient Checklist** has been successfully completed

Prior to EVERY infusion of TYSABRI:

Patient arrives for TYSABRI infusion

1 Confirm that the patient is currently **'Authorized'** to receive TYSABRI on TOUCH On-Line*

2 Provide the patient with the **Patient Medication Guide**

3 Complete the **Pre-infusion Patient Checklist** on TOUCH On-Line*

Infusion

ONLY upon successful completion of the **Pre-infusion Patient Checklist**:

- Start an IV line
- Mix TYSABRI

↓

Infuse TYSABRI over 1 hour and observe patient for 1 hour post-infusion


↓

Submit completed **Pre-infusion Patient Checklist** via TOUCH On-Line* within 1 business day

*Paper process: Check patient record for current **Notice of Patient Authorization** and fax completed **Pre-infusion Patient Checklist** to 1-800-840-1278.



Checking Patient Authorization Status



Only patients with a status **'Authorized'** can receive TYSABRI®

➤ Check patient status as **'Authorized'** on TOUCH On-Line



Paper process: **Notice of Patient Authorization** is faxed to both Prescriber and Infusion Site; a copy must be placed in the patient record

Touch PRESCRIBING PROGRAM
TYSABRI Outreach: Unified Commitment to Health

Phone: 1 800 458 2355 | Fax: 1 800 848 1278

By Facsimile **Notice of Patient Authorization** 9/19/2016
<INDICATION>

This TOUCH Prescribing Program authorization is valid from 1/01/2016 through 6/30/2016.

This notice is regarding only the patient's enrollment period in the TOUCH Prescribing Program and does not refer to the patient's insurance status or coverage.

Patient: Jennifer Patient Indication: <Indication>
Patient Enrollment Number: PTXXXXXXX Patient DOB: 1/1/1978

Account: Test Infusion Site
Site Authorization Number: ST123456
123 Infusion Site Lane
Durham, NC 27709
Account Phone: 555-555-1234 Account Fax: 555-555-1236

Prescriber: John Prescriber (MDXXXXXXX)
Prescriber Phone: 555-555-7896 Prescriber Fax: 555-555-7894

Today's Infusions							
(show the next 3 days)							
Patient Enrollment #	Last Name	First Name	Date of Birth	Status	Last Infusion Date	Next Infusion Date	Pre-Infusion Patient Checklist Status
[REDACTED]	PATIENT	JENNIFER	01/01/1978	Authorized	10/12/2007	09/28/2007	Start

1 patient found.



Pre-infusion Patient Checklist

Enroll

Infuse

Track



➤ All Infusion Sites must complete, sign, and submit the **Pre-infusion Patient Checklist** at every infusion visit

Patient Actions

This patient is currently Authorized to receive TYSABRI.

Yes No Has the patient received and read the Patient Medication Guide, including the section "What should I tell my doctor and nurse before each infusion of TYSABRI?"

Yes No 1. Over the past month, have you had any new or worsening medical problems (such as a new or sudden change in your thinking, eyesight, balance, strength, or other problems) that have persisted over several days?

Yes No 2. Do you have a medical condition that can weaken your immune system, such as HIV infection or AIDS, leukemia or lymphoma, or an organ transplant, that may suggest that your body is not able to fight infections well?

Yes No 3. In the past month, have you taken medicines to treat cancer or MS or any other medicines that weaken your immune system? ([Click here to review the list with the patient.](#))

Yes No Was TYSABRI infused?

09/26/2007 Date infused
(mm/dd/yyyy)


10/03/2007 Date of next infusion appointment
(mm/dd/yyyy)

Next > Cancel

➤ Submit form within 1 business day of patient's visit via TOUCH On-Line



Paper process: Fax page one to 1-800-840-1278 and place original in the patient's record



Verify and Sign the Pre-Infusion Patient Checklist

TOUCH On-Line username

Password




NOTE: Pre-infusion Patient Checklist **must** be completed and submitted whether or not the patient is infused.



Program Overview

- What is the TOUCH Prescribing Program?
- What tools support the TOUCH Prescribing Program?
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- What is the enrollment process?
- What is the process to infuse TYSABRI®?
- **How are patients tracked?**
- What is TOUCH On-Line?

Tracking Overview



Tracking Overview

Enroll

Infuse

Track

MS

Infusion Site

Pre-infusion Patient Checklist



Prescriber

Patient Status Report and Reauthorization Questionnaire



Prescriber


Initial and 6-Month Discontinuation Questionnaire



Crohn's disease


Prescriber

12-Week Questionnaire



NOTE: Missing or incomplete TOUCH Prescribing Program forms will prompt continued follow-up by a TOUCH Compliance Manager.

If a patient discontinues TYSABRI®, important health information is collected and tracked over time



 The prescriber will be sent **Discontinuation Questionnaires**, which must be completed and submitted to the TOUCH Prescribing Program via TOUCH On-Line

 Paper process: Upon notification of patient discontinuation, the **Discontinuation Questionnaire** will be faxed to the prescriber


- Fax completed form to 1-800-840-1278 and place original in the patient's file



***NOTE: Discontinuation Questionnaires are ONLY sent upon notification of discontinuation and again six months following discontinuation of TYSABRI**



Tracking Tools



Tracking Overview – MS

The TOUCH Prescribing Program will track all patients over time, so that Biogen can inform the FDA, prescribers, and patients in a timely manner of information regarding the safety of TYSABRI®.

Pre-infusion Patient Checklist (Every 28 days)

This form is titled 'TYSABRI Pre-infusion Patient Checklist'. It includes sections for 'Examples of' and 'Pre-infusion Patient Checklist'. The checklist contains various questions and checkboxes related to patient safety and medication management, such as 'Are you taking any other medications?' and 'Do you have any allergies?'. The Biogen logo is visible at the bottom left.

TYSABRI Patient Status Report and Reauthorization Questionnaire (Every 6 months)

This form is titled 'TYSABRI Patient Status Report and Reauthorization Questionnaire—MS'. It includes sections for 'MS Touch' and 'TYSABRI Patient Status Report and Reauthorization Questionnaire—MS'. The form contains a detailed questionnaire with checkboxes and a table for tracking symptoms. The Biogen logo is visible at the bottom left.


Initial and 6-Month Discontinuation Questionnaire*

This form is titled 'TYSABRI Discontinuation Questionnaire—MS'. It includes sections for 'MS Touch' and 'TYSABRI Discontinuation Questionnaire—MS'. The form contains a detailed questionnaire with checkboxes and text boxes for patient information and feedback. The Biogen logo is visible at the bottom left.



***NOTE: Discontinuation Questionnaires are ONLY sent upon notification of discontinuation and again six months following discontinuation of TYSABRI**

Tracking Tools



Tracking Overview – Crohn's Disease

The TOUCH Prescribing Program will track all patients over time, so that Biogen can inform the FDA, prescribers, and patients in a timely manner of information regarding the safety of TYSABRI®.

Pre-infusion Patient Checklist (Every 28 days)

The form includes sections for patient information, a checklist of symptoms and side effects (e.g., fever, chills, nausea, diarrhea), and a section for the prescriber to complete. It is titled 'TYSABRI Pre-infusion Patient Checklist'.

12-Week Questionnaire (After initial 12 weeks)

This questionnaire is titled 'TYSABRI 12-Week Questionnaire for Crohn's Disease'. It includes a section for patient information and a series of questions about the patient's health, including whether they have experienced any side effects or changes in their condition since starting treatment.

Patient Status Report and Reauthorization Questionnaire (Every 6 months)

This form is titled 'TYSABRI Patient Status Report and Reauthorization Questionnaire—Crohn's Disease'. It contains a detailed section for the prescriber to report on the patient's clinical status, including current symptoms, side effects, and overall health. It also includes a section for the patient to provide input on their treatment.

Initial and 6-Month Discontinuation Questionnaire*

This form is titled 'TYSABRI 6-Month Discontinuation Questionnaire'. It is used to gather information from the patient and the prescriber regarding the reasons for discontinuing treatment, the patient's current health, and any side effects experienced. It includes a section for the prescriber to provide a summary of the patient's history and treatment.



***NOTE: Discontinuation Questionnaires are ONLY sent upon notification of discontinuation and again six months following discontinuation of TYSABRI.**

Program Overview

- What is the TOUCH Prescribing Program?
- What tools support the TOUCH Prescribing Program?
 - MS TOUCH Educational Materials
 - CD TOUCH Educational Materials
- What is the enrollment process?
- What is the process to infuse TYSABRI®?
- How are patients tracked?
- **What is TOUCH On-Line?**
- How is TYSABRI acquired?

TOUCH On-Line Overview

- TOUCH On-Line is a Web-based tool designed to:
 - Provide real-time access to TYSABRI® patient data
 - Maintain compliance with the TOUCH Prescribing Program
 - Streamline communication to/from Prescribers and Infusion Sites
- TOUCH On-Line is available only to enrolled TOUCH participants
- TOUCH On-Line is accessed with secure user name and password

A screenshot of the TOUCH On-Line login interface. The form has a blue header with the text "Please Login to TOUCH On-Line". Below the header, there are two input fields: "TOUCH On-Line Username" and "Password". A blue link "Forgot your password?" is positioned below the password field. A blue "Login" button is located below the input fields. At the bottom of the form, there is a section titled "Having trouble logging in?" with the text: "Check with your Site Administrator or call us at 1-800-456-2255 Monday through Friday, 8:30 am to 8:00 pm EST."

Summary Review

- The TOUCH Prescribing Program makes TYSABRI® available only to prescribers, infusion sites, pharmacies associated with infusion sites, and patients who are enrolled in the program
- There are 3 main components of the program: Enroll – Infuse – Track
- TYSABRI must be administered only to patients who are enrolled in and meet all the conditions of the TOUCH Prescribing Program
- Indication-specific training and educational materials are required for a site to become authorized on MS TOUCH, CD TOUCH or both
- TOUCH On-Line is a web-based tool available only to authorized infusion sites and prescribers enrolled in TOUCH
- Only authorized infusion sites and their associated certified pharmacies may acquire TYSABRI



© 2006-2016 Biogen

10/2016

TYS-US-0482 V2

The logo for TYSABRI (natalizumab) features the word "TYSABRI" in a large, bold, blue, sans-serif font. A red swoosh with a blue arrowhead at its end curves over the top of the letters. Below "TYSABRI" is the text "(natalizumab)" in a smaller, blue, sans-serif font.

TYSABRI
(natalizumab)

Overview of the TOUCH Program

**Please see accompanying full Prescribing Information,
including Boxed Warning.**

TYSABRI[®]
(natalizumab)

INDICATIONS AND USAGE

Multiple Sclerosis (MS)

- TYSABRI (natalizumab) is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. See Full Prescribing Information regarding the risk of PML with TYSABRI

Crohn's Disease (CD)

- TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease (CD) with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF- α . TYSABRI should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine or methotrexate) or inhibitors of TNF- α

Why the program was developed

Biogen is committed to patient safety. The TOUCH[®] Prescribing Program was designed:


- To inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with longer treatment duration, prior immunosuppressant use, and the presence of anti-JCV antibodies
- To warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised
- To promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML

Prescribers, infusion sites, certified pharmacies associated with infusion sites, and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense, or receive TYSABRI. All completed Enrollment Forms must be faxed to Biogen at 1-800-840-1278.



- TOUCH On-Line is a web-based tool designed to:
 - Provide real-time access to TYSABRI patient data
 - Maintain compliance with the TOUCH Prescribing program
 - Reduce administrative burden/paperwork for Prescribers and Infusion Sites
- TOUCH On-Line is accessed with secure user name and password

How the program works



This Overview serves only as an introduction to the program. For additional details please see the full Prescribing Information, or call 1-800-456-2255.

Compliance with the requirements of the TOUCH Prescribing Program is necessary to maintain authorization to prescribe, dispense, infuse, or receive TYSABRI. Failure to comply with these requirements may result in de-enrollment from the TOUCH Prescribing Program and termination of such authorization.

For more information on the TOUCH Prescribing Program or to obtain additional copies of material, please contact your Biogen representative or call 1-800-456-2255. The Patient Medication Guide is also available online at www.TYSABRI.com.



1

Enrollment

All participants must enroll in the TOUCH Prescribing Program by completing an Enrollment Form.

Prescribers and Patients

Prior to enrollment, prescribers must receive and review the full Prescribing Information and educational materials relating to the TOUCH Prescribing Program. Before completing and signing a Prescriber/Patient Enrollment Form, prescribers and patients are required to:

- Understand and discuss the benefits and risks of treatment with TYSABRI, including PML and other opportunistic infections
- Understand and acknowledge their respective program responsibilities as outlined in the Enrollment Kit

Patients should be fully counseled by either the enrolled prescriber or a healthcare provider under that prescriber's direction before an initial prescription is written. A copy of the completed Prescriber/Patient Enrollment Form should be retained in the patient's medical record. Upon receipt of a properly completed Enrollment Form:

- A Patient Enrollment Number will be assigned
- A Biogen Case Manager will be assigned to assure that the patient is assigned to an authorized infusion site

Infusion Sites and Certified Pharmacies*

Before completing and signing their respective Enrollment Forms, infusion sites and associated certified pharmacies must receive training from a Biogen representative.

*A certified pharmacy is a pharmacy that is part of a hospital, group practice, or infusion site, and is affiliated with one or more infusion sites. Retail pharmacies, wholesalers, and specialty distributors are excluded from holding inventory and dispensing TYSABRI.

Please see accompanying full Prescribing Information, including Boxed Warning.

2

Infusion

Only infusion sites authorized by the TOUCH Prescribing Program can infuse TYSABRI. They are required to:

- Confirm that the patient is currently authorized to receive TYSABRI
- Provide the patient with a copy of the TYSABRI Patient Medication Guide prior to each infusion
- Administer the Pre-Infusion Patient Checklist to every patient prior to each infusion and submit it to Biogen within 1 business day, regardless of whether the patient is infused or not

Authorized infusion sites must use the Authorization Number that is provided upon enrollment to order and receive shipments of TYSABRI.* Certified pharmacies may only dispense TYSABRI to authorized, associated infusion sites.

*The TOUCH Prescribing Program utilizes a closed distribution system that restricts all product shipments. This system includes a single distributor, specialty pharmacies under contract with Biogen and authorized certified pharmacies associated with authorized infusion sites.

3

Tracking

The TOUCH Prescribing Program will track all patients over time so that Biogen can inform the FDA, prescribers, and patients in a timely manner of information regarding the safety of TYSABRI. Prescribers are required to report any case of PML, serious opportunistic infection, or death in TYSABRI-treated patients to Biogen or the FDA. Furthermore, prescribers are also required to cooperate in the investigation of potential adverse events including providing relevant information upon request. The primary tracking tools include:

- Pre-infusion Patient Checklist
- Patient Status Report and Reauthorization Questionnaire
- Initial and 6-month Discontinuation Questionnaires

Missing or incomplete forms will prompt TOUCH Case Managers to follow up with infusion sites, patients, and/or prescribers to obtain such information in compliance with program requirements.

Prescribers, infusion sites, and certified pharmacies may be audited by the FDA, Biogen, and/or a third party authorized by Biogen.

Important Responsibilities

PRESCRIBERS— Among the important responsibilities of prescribers in the TOUCH Prescribing Program are the following:

- Acknowledge that TYSABRI should only be prescribed in accordance with the FDA label
- Educate the patient on the benefits and risks of treatment with TYSABRI by using the Patient Medication Guide
- Evaluate the patient 3 and 6 months after the first infusion, and every 6 months thereafter, and for 6 months after TYSABRI has been discontinued
- Determine every 6 months whether the patient should continue on treatment, and if so, reauthorize treatment
- Submit to Biogen the TYSABRI Patient Status Report and Reauthorization Questionnaire 6 months after initiating treatment and every 6 months thereafter
- Report serious opportunistic infections and atypical infections with TYSABRI to Biogen at 1-800-456-2255 and to the Food and Drug Administration's MedWatch program at 1-800-FDA-1088

PATIENTS—Among the important responsibilities of patients in the TOUCH Prescribing Program are the following:

- Bring to each infusion a list of all medicines and treatments they have taken during the last month
- Read the Patient Medication Guide before starting TYSABRI and before each TYSABRI infusion
- Promptly report any continuously worsening symptoms that persist over several days to their prescriber
- Inform all of their physicians that they are receiving TYSABRI
- Plan to see their prescriber 3 and 6 months after the first infusion, and at least as frequently as every 6 months thereafter

INFUSION SITES—Among the important responsibilities of infusion sites in the TOUCH Prescribing Program are the following:

- Confirm that the patient is currently authorized to receive TYSABRI
- Provide the patient with a copy of the TYSABRI Patient Medication Guide *prior to each infusion*
- Administer the Pre-infusion Patient Checklist to every patient prior to each infusion and submit to Biogen within 1 business day, regardless of whether the patient is infused or not

Please see accompanying full Prescribing Information, including Boxed Warning.



Patient Information

Date of birth: _____ / _____ / _____
 (MM/DD/YYYY)

Patient name: _____
 First MI Last

Street address: _____

City _____ State _____ ZIP _____

Work telephone - -

Home telephone - -

Patient may be contacted at Home Work Best time: _____

Female Male

E-mail address _____

Insurance Information

Patient SSN - -

Please attach copies of both sides of patient's insurance and pharmacy card(s).

Check if no insurance Medicare Medicaid _____
 Medicaid Plan Type

Policyholder's name: _____
 First MI Last

Primary insurance _____ Insurance company telephone _____

Policy number _____ Group number _____

Pharmacy benefit manager _____

Patient Authorization to Use/Disclose Health Information

I understand that I have certain rights related to the collection, use, and disclosure of my medical and health information. This information is called "protected health information" (PHI) and includes demographic information (such as sex, race, date of birth, etc.), the results of physical examinations, clinical tests, blood tests, X-rays, and other diagnostic and medical procedures that may be included in my medical records. Biogen will not use my PHI without my consent.

This Authorization form applies to PHI created or obtained by my prescriber, my infusion site, my pharmacy, and my health insurance company. I understand that by signing this Authorization, I authorize my prescriber, infusion site, pharmacy, and/or health insurance company to disclose the PHI in my medical records to Biogen and its representatives or agents, including information related to my medical condition, treatment, and health insurance, as well as all information provided on any prescription. I also authorize Biogen to use this information to provide TYSABRI support services, such as investigating insurance coverage for TYSABRI and coordinating delivery of TYSABRI to the prescriber or infusion site administering TYSABRI (which may include forwarding my health information to a pharmacy).

I agree to allow Biogen to ask me about and provide me with these support services, educational kits, and other information related to TYSABRI and/or my medical condition. I understand that, once my PHI has been disclosed to Biogen, federal privacy laws may no longer protect the information. However, Biogen agrees to protect my PHI by using it only for the purposes authorized in this Authorization or as required by law.

I understand that I may refuse to sign this Authorization, and refusing to do so will affect my eligibility to receive these additional services but will not affect my ability to receive TYSABRI. I understand that signing this Authorization will not change how my healthcare providers, health insurance plan, and pharmacies provide my medical treatment or payment for treatment or insurance benefits.

I understand that I may cancel all or a part of this Authorization at any time by mailing a letter requesting such cancellation to TYSABRI Support Services, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC 27709. If I cancel this Authorization, Biogen will end further use and disclosure of my PHI as soon as possible. This will not affect health information that has already been used or disclosed in reliance upon this Authorization.

I will receive a copy of this signed Authorization. This Authorization expires ten (10) years from the date this Authorization is signed.

Patient signature (or personal representative): _____ Date: _____

Authority of personal representative (if applicable): _____

Patient Acknowledgment

Biogen considers patient safety a priority. Read each section below and initial in the space provided if you understand the information. Do not sign this form if there is anything you do not understand about all the information you have received. Ask your doctor about anything you do not understand before you initial and sign this form.

I understand that TYSABRI is a medicine approved to treat patients with relapsing forms of multiple sclerosis (MS).

- I have talked to my doctor and understand the benefits and risks of TYSABRI treatment
- TYSABRI increases the risk of PML. I understand that when starting and continuing treatment with TYSABRI, I should talk to my doctor about whether the expected benefit of TYSABRI is enough to outweigh this risk (see important information about PML below).

Initials: _____

I understand that TYSABRI increases my chance of getting a rare brain infection that usually leads to death or severe disability.

- This infection is called progressive multifocal leukoencephalopathy (PML). PML usually happens in people with weakened immune systems
 - There is no known treatment, prevention, or cure for PML
 - My chance for getting PML may be higher if I am also being treated with other medicines that can weaken my immune system, including other MS treatments. Even if I use TYSABRI alone to treat my MS, I can still get PML
 - My chance for getting PML increases if I:
 - Have received TYSABRI for a long time, especially longer than 2 years
 - Have received certain medicines that can weaken my immune system before I start receiving TYSABRI
 - Have been exposed to John Cunningham Virus (JCV). JCV is a common virus that is harmless in most people but can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Most people who are exposed to JCV do not know it or have any symptoms. This exposure usually happens in childhood. My doctor may do a blood test to check if I have been exposed to JCV before I start receiving TYSABRI or during my treatment
- My risk of getting PML is greatest if I have all 3 risk factors listed above. There may be other risk factors for getting PML during TYSABRI treatment that we do not know about yet. My doctor should discuss the risks and benefits of TYSABRI treatment with me before I decide to receive TYSABRI
- I should call my doctor right away if I get any new or worsening symptoms that last several days, especially nervous system symptoms, while I am taking TYSABRI, and for at least 6 months after I stop taking TYSABRI. Some of these symptoms include a new or sudden change in my thinking, eyesight, balance, or strength, but I should also report other new or worsening symptoms

Initials: _____

To receive TYSABRI, all patients must be enrolled in a restricted program called the TOUCH Prescribing Program.

- The TOUCH Prescribing Program is run by the company that makes TYSABRI. Under this program, the company is required to collect information about my health at regular time periods. I cannot receive TYSABRI if I do not agree to follow the requirements of the TOUCH Prescribing Program. I understand that the TOUCH Prescribing Program does not require me to sign the Authorization included on page 1 of this form
- The company may use my information to meet the requirements of the TOUCH Prescribing Program, including helping me locate an authorized infusion site
- I must notify the TOUCH Prescribing Program if I switch physicians or infusion sites
- I have received, read, and understand the Patient Medication Guide
- I will bring to each TYSABRI infusion a list of all medicines and treatments that I have taken during the last month

Initials: _____

Patient name: _____ **Date of birth:** _____ / _____ / _____
First MI Last (MM/DD/YYYY)

Patient signature (or personal representative): _____ **Date:** _____

Authority of personal representative (if applicable): _____

Prescriber/Patient Enrollment Form—MS

Please submit this form to:
 Biogen
 www.touchprogram.com
 Fax: 1-800-840-1278

Completion of all pages is required.

Patient name: _____ DOB: ____/____/____
First MI Last (MM/DD/YYYY)

Date of first MS symptoms: ____/____/____
(MM/DD/YYYY)

Please indicate the patient's **MOST RECENT** therapy for MS (if patient was most recently on combination therapy, check all that apply). None

- AVONEX® PLEGRIDY® Betaseron® Copaxone® Rebif® TY SABRI® Extavia® Gilenya®
 TECFIDERA® Aubagio® LEMTRADA® Azathioprine Methotrexate Mitoxantrone Mycophenolate
 Cyclophosphamide ZINBRYTA™ Other

Please indicate the start and stop dates of most recent therapy: Start date: / Stop date: /
M M Y Y Y Y M M Y Y Y Y

Has the patient ever received TY SABRI before? Yes No

Has the patient **EVER** been prescribed an immunosuppressant or an antineoplastic therapy for any condition? Yes No

If yes, please check all of the following that apply:

- Azathioprine Cyclophosphamide Methotrexate Mitoxantrone Mycophenolate Other

Has the patient **EVER** been tested for the presence of anti-JCV antibodies? Yes No Unknown

If yes, has the patient **EVER** tested **POSITIVE** for the presence of anti-JCV antibodies? Yes No Pending

Prescription for TY SABRI

Dose: TY SABRI® (natalizumab) 300 mg Dispense: 1 vial Refills: 12 Directions: IV infusion per Prescribing Information every 4 weeks

I authorize Biogen as my designated agent and on behalf of my patient to (1) use the information on this form to enroll the above-named patient in the TOUCH Prescribing Program, (2) furnish any information on this form to the insurer of the above-named patient, (3) forward the information on this form to the prescriber or infusion site administering TY SABRI, if applicable, (4) forward the above prescription by fax or by another mode of delivery to a pharmacy, if applicable, and (5) coordinate delivery of TY SABRI on behalf of the above-named patient.

Prescriber signature (Stamps not acceptable): _____ Date: _____

Prescriber

Prescriber name: _____ Office contact _____
First MI Last

Street address _____ Tax ID # _____

City _____ State _____ ZIP _____ DEA # _____

Telephone -- NPI/UPIN/provider ID # with patient's insurer(s) _____
 Fax --

Continued on next page

Patient Information

Date of birth: _____ / _____ / _____ Patient name: _____
(MM/DD/YYYY) First MI Last

In addition, I allow the sharing of my health information to the person or people I name below. Biogen may contact the people named below to discuss my enrollment in the TOUCH Program.

Designated Individual (print name): _____ Relationship: _____

Infusion Site Information*

1 Prescriber will administer TYSABRI and request the following services (check only one):

- No services required OR Forward this prescription to a specialty pharmacy OR Please conduct insurance research and procurement options for TYSABRI
provider to investigate pharmacy coverage and coordinate delivery to prescriber's office

OR

2 Prescriber will refer TYSABRI treatment to another site (check only one):

- I require assistance in locating an infusion site OR I am referring the patient to the following infusion site or healthcare provider:

Name of administering healthcare provider (first, last) Office contact

Site name Telephone --

Street address or site Authorization Number Fax --

City State ZIP

*Note: TYSABRI can only be infused at authorized infusion sites. Biogen will contact you if the infusion site you have indicated is not authorized to infuse TYSABRI.

Please see Prescribing Information, including Boxed Warning, for important safety information.



All other trademarks are the marks of their respective owners.

© 2006-2016 Biogen

10/2016



Patient Information

Date of birth: _____ / _____ / _____
 (MM/DD/YYYY)

Patient name: _____
 First MI Last

Street address _____

City _____ State _____ ZIP _____

Work telephone - -

Home telephone - -

Patient may be contacted at Home Work Best time: _____

Female Male

E-mail address _____

Insurance Information

Patient SSN - -

Please attach copies of both sides of patient's insurance and pharmacy card(s).

Check if no insurance Medicare Medicaid _____
 Medicaid Plan Type _____

Policyholder's name: _____
 First MI Last

Primary insurance _____ Insurance company telephone _____

Policy number _____ Group number _____

Pharmacy benefit manager _____

Patient Authorization to Use/Disclose Health Information

I understand that I have certain rights related to the collection, use, and disclosure of my medical and health information. This information is called "protected health information" (PHI) and includes demographic information (such as sex, race, date of birth, etc.), the results of physical examinations, clinical tests, blood tests, X-rays, and other diagnostic and medical procedures that may be included in my medical records. Biogen will not use my PHI without my consent.

This Authorization form applies to PHI created or obtained by my prescriber, my infusion site, my pharmacy, and my health insurance company. I understand that by signing this Authorization, I authorize my prescriber, infusion site, pharmacy, and/or health insurance company to disclose the PHI in my medical records to Biogen and its representatives or agents, including information related to my medical condition, treatment, and health insurance, as well as all information provided on any prescription. I also authorize Biogen to use this information to provide TYSABRI support services, such as investigating insurance coverage for TYSABRI and coordinating delivery of TYSABRI to the prescriber or infusion site administering TYSABRI (which may include forwarding my health information to a pharmacy).

I agree to allow Biogen to ask me about and provide me with these support services, educational kits, and other information related to TYSABRI and/or my medical condition. I understand that, once my PHI has been disclosed to Biogen, federal privacy laws may no longer protect the information. However, Biogen agrees to protect my PHI by using it only for the purposes authorized in this Authorization or as required by law.

I understand that I may refuse to sign this Authorization, and refusing to do so will affect my eligibility to receive these additional services but will not affect my ability to receive TYSABRI. I understand that signing this Authorization will not change how my healthcare providers, health insurance plan, and pharmacies provide my medical treatment or payment for treatment or insurance benefits.

I understand that I may cancel all or a part of this Authorization at any time by mailing a letter requesting such cancellation to TYSABRI Support Services, 5000 Davis Drive, PO Box 13919, Research Triangle Park, NC 27709. If I cancel this Authorization, Biogen will end further use and disclosure of my PHI as soon as possible. This will not affect health information that has already been used or disclosed in reliance upon this Authorization.

I will receive a copy of this signed Authorization. This Authorization expires ten (10) years from the date this Authorization is signed.

Patient signature (or personal representative): _____ Date: _____
 Authority of personal representative (if applicable): _____

Patient Acknowledgment

Biogen considers patient safety a priority. Read each section below and initial in the space provided if you understand the information.

Do not sign this form if there is anything you do not understand about all the information you have received. Ask your doctor about anything you do not understand before you initial and sign this form.

I understand that TYSABRI is a medicine approved to treat patients with moderate to severe Crohn's disease who have not been helped enough by, or cannot tolerate, usual Crohn's disease medicines and medicines called tumor necrosis factor (TNF) inhibitors.

- I have talked to my doctor and understand the benefits and risks of TYSABRI treatment
- I understand that I should not take certain medicines that weaken the immune system while I am taking TYSABRI

Initials: _____

I understand that TYSABRI increases my chance of getting a rare brain infection that usually leads to death or severe disability.

- This infection is called progressive multifocal leukoencephalopathy (PML). PML usually happens in people with weakened immune systems
- There is no known treatment, prevention, or cure for PML
- My chance for getting PML may be higher if I am also being treated with other medicines that can weaken my immune system, including other Crohn's disease treatments. Even if I use TYSABRI alone to treat my CD, I can still get PML
- My chance for getting PML increases if I:
 - Have received TYSABRI for a long time, especially longer than 2 years
 - Have received certain medicines that can weaken my immune system before I start receiving TYSABRI
 - Have been exposed to John Cunningham Virus (JCV). JCV is a common virus that is harmless in most people but can cause PML in people who have weakened immune systems, such as people taking TYSABRI. Most people who are exposed to JCV do not know it or have any symptoms. This exposure usually happens in childhood. My doctor may do a blood test to check if I have been exposed to JCV before I start receiving TYSABRI or during my treatment.

My risk of getting PML is greatest if I have all 3 risk factors listed above. There may be other risk factors for getting PML during TYSABRI treatment that we do not know about yet. My doctor should discuss the risks and benefits of TYSABRI treatment with me before I decide to receive TYSABRI

- I should call my doctor right away if I get any new or worsening symptoms that last several days, especially nervous system symptoms, while I am taking TYSABRI and for at least 6 months after I stop taking TYSABRI. Some of these symptoms include a new or sudden change in my thinking, eyesight, balance, or strength, but I should also report other new or worsening symptoms

Initials: _____

To receive TYSABRI, all patients must be enrolled in a restricted program called the TOUCH® Prescribing Program.

- The TOUCH Prescribing Program is run by the company that makes TYSABRI. Under this program, the company is required to collect information about my health at regular time periods. **I cannot receive TYSABRI if I do not agree to follow the requirements of the TOUCH Prescribing Program.** I understand that the TOUCH Prescribing Program does not require me to sign the Authorization included on page 1 of this form
- The company may use my information to meet the requirements of the TOUCH Prescribing Program, including helping me locate an authorized infusion site
- I must notify the TOUCH Prescribing Program if I switch physicians or infusion sites
- I have received, read, and understand the Patient Medication Guide
- I will bring to each TYSABRI infusion a list of all medicines and treatments that I have taken during the last month

Initials: _____

Patient name: _____ **Date of birth:** _____ / _____ / _____
First MI Last (MM/DD/YYYY)

Patient signature (or personal representative): _____ **Date:** _____

Authority of personal representative (if applicable): _____

Patient History

Patient name: _____ DOB: ____/____/____
First MI Last (MM/DD/YYYY)

Date of first Crohn's disease symptoms: _____
(MM/YYYY)

Please indicate the patient's Crohn's disease therapy(ies) within the past one year AND whether the therapy is ongoing or stopped. **Ongoing therapies, except corticosteroids, must be stopped before starting TYSABRI.** (If patient was on multiple therapies, check all that apply.)

Medication	Ongoing	OR	Stopped	Medication	Ongoing	OR	Stopped
<input type="checkbox"/> None				Methotrexate	<input type="checkbox"/>		<input type="checkbox"/>
Remicade®	<input type="checkbox"/>		<input type="checkbox"/>	Systemic steroids	<input type="checkbox"/>		<input type="checkbox"/>
Humira®	<input type="checkbox"/>		<input type="checkbox"/>	Entyvio®	<input type="checkbox"/>		<input type="checkbox"/>
Azathioprine or Mercaptopurine or Thioguanine	<input type="checkbox"/>		<input type="checkbox"/>	Other immunomodulatory therapy or immunosuppressant therapy (not including aminosalicylates)	<input type="checkbox"/>		<input type="checkbox"/>
Cimzia®	<input type="checkbox"/>		<input type="checkbox"/>				

Has the patient had a surgery for Crohn's disease within the previous year? Yes No

Has the patient ever received TYSABRI before? Yes No

Has the patient **EVER** been prescribed an immunosuppressant or an antineoplastic therapy for any condition? Yes No

If yes, please check all of the following that apply:

Remicade Humira Azathioprine or Mercaptopurine or Thioguanine Cimzia Methotrexate

Systemic steroids Vedolizumab (Entyvio®) Other

Has the patient **EVER** been tested for the presence of anti-JCV antibodies? Yes No Unknown

If yes, has the patient **EVER** tested **POSITIVE** for the presence of anti-JCV antibodies? Yes No Pending

Prescription for TYSABRI

Dose: TYSABRI® (natalizumab) 300 mg Dispense: 1 vial Refills: 12 Directions: IV infusion per Prescribing Information every 4 weeks

I authorize Biogen as my designated agent and on behalf of my patient to (1) use the information on this form to enroll the above-named patient in the TOUCH Prescribing Program, (2) furnish any information on this form to the insurer of the above-named patient, (3) forward the information on this form to the prescriber or infusion site administering TYSABRI, if applicable, (4) forward the above prescription by fax or by another mode of delivery to a pharmacy, if applicable, and (5) coordinate delivery of TYSABRI on behalf of the above-named patient.

Prescriber signature (stamps not acceptable): _____ Date: _____

Prescriber

Prescriber name: _____
First MI Last

Office contact _____

Street address _____

Tax ID # _____

City _____ State _____ ZIP _____

DEA # _____

Telephone --
 Fax --

NPI/UPIN/provider ID # with patient's insurer(s) _____

Prescriber Acknowledgment

- I have read and understand the full Prescribing Information for TYSABRI
- I understand that TYSABRI is indicated for adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies and inhibitors of TNF-α
- I understand that patients receiving TYSABRI should not take concomitant immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-α
- I understand that this patient has moderately to severely active Crohn's disease with evidence of inflammation
- I understand that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. When initiating and continuing treatment with TYSABRI, I should consider whether the expected benefit of TYSABRI is sufficient to offset this risk
- I am aware that cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI monotherapy
- I understand that three risk factors identified thus far that increase the risk of PML in TYSABRI-treated patients are:
 - Longer treatment duration, especially beyond 2 years
 - Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil)
 - The presence of anti-JCV antibodies
 These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI
- I understand that MRI findings may be apparent before clinical signs or symptoms. Periodic monitoring for radiographic signs consistent with PML should be considered to allow for an early diagnosis of PML. Lower PML-related mortality and morbidity have been reported following TYSABRI discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis.
- I have discussed other Crohn's disease treatments with this patient
- To my knowledge, this patient has no known contraindications to TYSABRI treatment, including PML
- I have instructed this patient to promptly report to me any continuously worsening symptoms that persist over several days, especially nervous system symptoms
- I understand that this patient should be seen and evaluated 3 months after the first infusion, 6 months after the first infusion, every 6 months thereafter, and for at least 6 months after TYSABRI has been discontinued
- I understand that TYSABRI should be discontinued if the patient has not experienced a therapeutic benefit by 12 weeks of therapy
- I will determine every 6 months whether this patient should continue on TYSABRI and if so, authorize treatment for another 6 months. I understand that I am required to submit an "Initial Discontinuation Questionnaire" when TYSABRI is discontinued and a "6-Month Discontinuation Questionnaire" following discontinuation of TYSABRI
- I understand that patients receiving steroid therapy at the time of TYSABRI initiation must undergo a steroid-tapering regimen once a therapeutic response is achieved. If the patient with Crohn's disease cannot be tapered off steroids within 6 months of starting TYSABRI, TYSABRI should be discontinued
- I should report, as soon as possible, cases of PML, hospitalizations due to opportunistic infection, and any death to Biogen
- I understand that data concerning this patient and me will be entered into the mandatory TOUCH Prescribing Program. Biogen requires my cooperation with periodic data collection. Failure to provide the requested information or otherwise comply with the requirements of the TOUCH Prescribing Program may result in discontinuation of TYSABRI treatment for this patient and termination of my authorization to prescribe TYSABRI
- I have received educational materials regarding the benefits and risks of TYSABRI treatment
- I have, or another healthcare provider under my direction has, educated this patient on the benefits and risks of treatment with TYSABRI, provided him or her with the Patient Medication Guide and Enrollment Form, instructed him or her to read these materials, and encouraged him or her to ask questions when considering TYSABRI

Patient name: _____ **Date of birth:** _____ / _____ / _____
First MI Last (MM/DD/YYYY)
Prescriber signature: _____ **Date:** _____

Patient Information

Date of birth: _____ / _____ / _____ Patient name: _____
 (MM/DD/YYYY) First MI Last

In addition, I allow the sharing of my health information to the person or people I name below. Biogen may contact the people named below to discuss my enrollment in the TOUCH Program.

Designated Individual (print name): _____ Relationship: _____

Infusion Site Information*

- 1 Prescriber will administer TYSABRI and request the following services (check only one):**
 No services required OR Forward this prescription to a specialty pharmacy provider OR Please conduct insurance research and procurement options for TYSABRI to investigate pharmacy coverage and coordinate delivery to prescriber's office

- 2 Prescriber will refer TYSABRI treatment to another site (check only one):**
 I require assistance in locating an infusion site OR I am referring the patient to the following infusion site or healthcare provider

Name of infusion site or healthcare provider (first, last) _____ Office contact _____
 Street address or Site Authorization Number _____ Telephone --
 City _____ State _____ ZIP _____ Fax --

*Note: TYSABRI can only be infused at authorized infusion sites. Biogen will contact you if the infusion site you have indicated is not authorized to infuse TYSABRI.

Please see Prescribing Information, including Boxed Warning, for important safety information.



All other trademarks are the marks of their respective owners.



TYSABRI
Pre-infusion Patient Checklist

Please submit this form to:
Biogen
www.touchprogram.com
Fax: 1-800-840-1278

Patient name: _____ Patient Enrollment Number: _____
First MI Last (Issued by Biogen. Call 1-800-456-2255 or log on to www.touchprogram.com if number is not on file.)

Site name: _____ Site Authorization Number: _____

As a condition of your site's authorization to infuse **TYSABRI®** (natalizumab), this Pre-infusion Patient Checklist **must** be completed for each patient prior to each infusion. This page **must** be submitted on-line (www.touchprogram.com) **OR** faxed to Biogen (1-800-840-1278) **within 1 day** of the patient's visit and a copy retained in the patient's record whether the patient has been infused or not.

STEP 1: Ensure that the patient is currently authorized to receive **TYSABRI for MS or Crohn's disease.**

You must refer to the patient's record prior to every infusion.

- If the patient did not receive his or her previous infusion, and physician clearance was required, you must confirm authorization from the prescriber before providing the current infusion
- Confirm the patient status is listed as "Authorized" on TOUCH On-Line (www.touchprogram.com) **OR**
- Confirm that there is a current **Notice of Patient Authorization** on file and that you have not received a **Notice of Patient Discontinuation** (paper-based process)

Is the patient currently authorized to receive **TYSABRI**?

Yes No

Yes Continue to next question.

No STOP—DO NOT INFUSE. If authorization cannot be verified on-line at www.touchprogram.com **OR** by calling 1-800-456-2255, the patient must be referred back to the healthcare provider who prescribed **TYSABRI**.

STEP 2: Confirm that the patient has read and understood the Patient Medication Guide.

The patient must read the Patient Medication Guide prior to every infusion. **Has the patient received and read the Patient Medication Guide, including the section "What should I tell my doctor and nurse before each infusion of **TYSABRI**?"**

Yes Continue to next question.

Yes No

No STOP—provide the Patient Medication Guide. Proceed to the next question after the patient has read it.

STEP 3: Read aloud and mark "Yes" or "No" for the patient's answers to the following questions:

- | | | |
|---|------------------------------|-----------------------------|
| 1. Over the past month, have you had any new or worsening medical problems (such as a new or sudden change in your thinking, eyesight, balance, strength, or other problems) that have persisted over several days? | Yes <input type="checkbox"/> | No <input type="checkbox"/> |
| 2. Do you have a medical condition that can weaken your immune system, such as HIV infection or AIDS, leukemia or lymphoma, or an organ transplant, that may suggest that your body is not able to fight infections well? | Yes <input type="checkbox"/> | No <input type="checkbox"/> |

Crohn's disease ONLY

Yes No

3. In the past month have you taken, or are you currently on, any medicines other than steroid medicines, to treat cancer or **Crohn's disease** or any other medicines that weaken your immune system? (Review the list on the next page with the patient.)

MS ONLY

Yes No

3. In the past month, have you taken medicines to treat cancer or **MS** or any other medicines that weaken your immune system? (Review the list on the next page with the patient.)

STEP 4: Record infusion information.

If the patient answered **YES** to question 1, 2 or 3, **DO NOT INFUSE**. Contact the healthcare provider who prescribed **TYSABRI** and review the patient's answers.

Yes No

➤ After discussing the patient's answers, did the prescriber authorize the patient to be infused?

➤ Check here if you were unable to contact the prescriber. (See next page for further instructions.)

Date infused (MM/DD/YYYY): _____ / _____ / _____

Not infused

If the next infusion has been scheduled, please enter date (MM/DD/YYYY): _____ / _____ / _____

Name and signature of staff completing checklist: _____ **Date:** _____

STEP 5: Submit the Pre-infusion Patient Checklist to Biogen on-line at www.touchprogram.com **OR fax to 1-800-840-1278.**

Please review the following list with the patient when asking question 3.

Examples of Immunosuppressants, Antineoplastics, and Immunomodulators

Multiple Sclerosis

Approved MS Therapies:

Daclizumab (ZINBRYTA™)
Dimethyl Fumarate (TECFIDERA®)
Glatiramer acetate (Copaxone®)
Interferon beta-1a (Rebif®, AVONEX®)
Interferon beta-1b (Betaseron®, Extavia®)
Fingolimod (Gilenya®)
Mitoxantrone (Novantrone®)
Peginterferon beta-1a (PLEGRIDY®)
Alemtuzumab (LEMTRADA®)
Teriflunomide (Aubagio®)

Immunosuppressants/Antineoplastics:

Azathioprine (Imuran®, Azasan®)
Cladribine (Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®)
Cyclosporine (Sandimmune®, Neoral®)
Fludarabine phosphate (Fludara®)
Leflunomide (Arava®)
Mercaptopurine (Purinethol®)
Methotrexate (Methotrex®, Rheumatrex®, Trexall®)
Mycophenolate mofetil (CellCept®)
Pemetrexed (Alimta®)

Additional Immunomodulators and Immunosuppressants:

Other interferons (Actimmune®, Infergen®, Intron® A,
Pegasys®, PEG-Intron®, Rebetron®, Roferon®-A)
Adalimumab (Humira®)
Alefacept (Amevive®)
Alemtuzumab (Campath®)
Anakinra (Kineret®)
Daclizumab (Zenapax®)
Efalizumab (Raptiva®)
Etanercept (Enbrel®)
Infliximab (Remicade®)
Intravenous immunoglobulin (IVIG)
Rituximab (Rituxan®)
Trastuzumab (Herceptin®)

Crohn's Disease

Approved TNF-α inhibitors for Crohn's disease:

Infliximab (Remicade®)
Adalimumab (Humira®)

Immunosuppressants/Antineoplastics:

Approved TNF-α inhibitors
Azathioprine (Imuran®, Azasan®)
Chlorambucil (Leukeran®)
Cladribine (Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®)
Cyclosporine (Sandimmune®, Neoral®)
Fludarabine phosphate (Fludara®)
Leflunomide (Arava®)
Mercaptopurine (Purinethol®)
Methotrexate (Methotrex®, Rheumatrex®, Trexall®)
Mycophenolate mofetil (CellCept®)
Pemetrexed (Alimta®)
Thioguanine (Tabloid®)

Additional Immunomodulators and Immunosuppressants:

Interferon beta-1a (Rebif®, AVONEX®)
Interferon beta-1b (Betaseron®)
Alefacept (Amevive®)
Abatacept (Orencia®)
Anakinra (Kineret®)
Daclizumab (Zenapax®)
Efalizumab (Raptiva®)
Etanercept (Enbrel®)
Glatiramer acetate (Copaxone®)
Intravenous immunoglobulin (IVIG)
Mitoxantrone (Novantrone®)
Other interferons (Actimmune®, Infergen®, Intron® A,
Pegasys®, PEG-Intron®, Rebetron®, Roferon®-A)
Rituximab (Rituxan®)
Trastuzumab (Herceptin®)
Vedolizumab (Entyvio®)

This list does not include all drugs that can suppress the immune system.

- Patients should consult their prescribing physician regarding drugs that may be taken concurrently with TYSABRI
- If there are any questions regarding concurrent therapy, **do not infuse** at this time and consult the healthcare provider who prescribed TYSABRI

If you are unable to contact the prescriber:

Instruct the patient to contact his/her prescriber and to reschedule an infusion as soon as possible. Continue efforts to reach the prescriber to inform him/her of the reason(s) for not infusing this patient. You will need to confirm authorization from the prescriber on the subsequent infusion.

This Pre-infusion Patient Checklist is not intended to replace the infusion site's general infusion protocol(s). Nor is this Pre-infusion Patient Checklist intended to be a substitute for consultation and review of reference materials and medical literature pertaining to individual clinical circumstances. Healthcare providers should make all treatment decisions based on the context of the situation and their clinical judgment.

Please do not make any extraneous marks on the Pre-infusion Patient Checklist. If there is information that you would like to share with Biogen and the TOUCH Prescribing Program, please contact us at 1-800-456-2255.

Please see accompanying full Prescribing Information, including Boxed Warning, for important safety information.

Helpful Information for evaluation of new neurological symptoms in patients receiving TYSABRI

This information is provided as an educational resource for healthcare providers and should be considered current as of the date listed herein. It is not intended to be a substitute for consultation and review of reference materials and medical literature pertaining to individual clinical circumstances. Healthcare providers should make all treatment decisions based on the context of the situation and their own clinical judgment.



**Please see accompanying full Prescribing Information,
including Boxed Warning.**

Background information

Progressive multifocal leukoencephalopathy (PML)

PML is a demyelinating disease that attacks the central nervous system (CNS). It is caused by a polyomavirus called the JC virus (JCV), which is common and widespread in humans. JCV usually remains latent, typically causing PML only in the setting of immunodeficiency.

The clinical picture of PML or other neurological conditions can be difficult to distinguish from multiple sclerosis (MS), especially early in the disease course. Therefore, this information is intended to offer an overview of some of the key issues regarding the definitive diagnosis of PML, especially as they relate to treatment with TYSABRI. These include:

- Patient monitoring and management
 - Obtaining a pretreatment MRI
 - Performing regular follow-ups
 - Treatment of relapses or other neurological symptoms
- Evaluation of new neurological symptoms in patients receiving TYSABRI
 - Distinguishing PML from MS
 - Suggested diagnostic algorithm
 - Action steps if PML is suspected, including MRI assessment, JCV testing, and plasma exchange (PLEX)
 - Immune Reconstitution Inflammatory Syndrome (IRIS)

Adapted from Kappos L et al. *Lancet Neurol.* 2007;6(5):431-441.

Please see accompanying full Prescribing Information, including Boxed Warning.

Patient monitoring and management

Management of patients receiving TYSABRI

Pretreatment MRI

Obtaining a pretreatment brain MRI scan is recommended. It may assist in determining whether MRI lesions noted at the time of new neurological signs or symptoms were preexistent. This may assist in the differential diagnosis between PML and MS activity.

Regular follow-ups

All patients treated with TYSABRI should have regular clinical follow-ups to allow for early detection of changes in neurological status. To that end, Biogen in conjunction with the Food and Drug Administration (FDA), developed a risk management plan for the United States called the TOUCH[®] Prescribing Program. As part of the TOUCH Prescribing Program:

- Physicians evaluate the patient 3 months after the first infusion, 6 months after the first infusion, every 6 months thereafter, and for at least 6 months after discontinuing Tysabri.
- Physicians submit the TYSABRI Patient Status Report and Reauthorization Questionnaire to Biogen 6 months after initiating treatment and every 6 months thereafter, ensuring additional monitoring and reporting by Biogen
- Infusion sites administer the Pre-Infusion Patient Checklist and report to the prescriber any changes in the patient's status prior to infusing
 - Infusion sites will not infuse TYSABRI if the patient reports a change in symptoms, unless the prescriber authorizes the infusion

Patient history

Knowing the history and pattern of prior and ongoing MS signs and symptoms can help in the management of patients treated with TYSABRI.

Please see accompanying full Prescribing Information, including Boxed Warning.



Evaluation of new neurological symptoms in patients receiving TYSABRI

- If new neurological symptoms develop, withhold TYSABRI dosing and evaluate the patient

Distinguishing PML from MS

The following information should be considered when undertaking the assessment and management of new or worsening neurological symptoms in MS patients treated with TYSABRI. There are no pathognomonic signs or symptoms that distinguish an MS relapse from PML, but there are certain clinical features that may help differentiate between the 2 conditions (see Table 1).

Table 1. Clinical signs and symptoms typical of MS relapse and PML

	MS relapse	PML
ONSET	Acute	Subacute
EVOLUTION	<ul style="list-style-type: none"> ➤ Over hours to days ➤ Normally stabilize ➤ Resolve spontaneously or with treatment 	<ul style="list-style-type: none"> ➤ Days to weeks ➤ Progressive
CLINICAL PRESENTATION	<ul style="list-style-type: none"> ➤ Diplopia ➤ Paresthesia ➤ Paraparesis ➤ Optic neuritis ➤ Myelopathy 	<ul style="list-style-type: none"> ➤ Cortical symptoms/signs ➤ Behavioral and neuropsychological alteration ➤ Retrochiasmal visual deficits ➤ Seizures ➤ Hemiparesis

Not intended to be inclusive of all clinical signs and symptoms indicative of MS and PML.

Please see accompanying full Prescribing Information, including Boxed Warning.

Treatment of MS relapse

- Relapses should be managed according to usual clinical practice

If treating with corticosteroids:

- A single short course of corticosteroids can be considered for cases in which PML is unlikely on clinical grounds
- Progression of symptoms, despite treatment with corticosteroids, should trigger further investigation


- In addition to PML and MS, other medical and CNS conditions including other infections should be considered when evaluating a patient with new neurological symptoms

New or recurrent neurological symptoms should prompt careful evaluation.

Please see accompanying full Prescribing Information, including Boxed Warning.

**TYSABRI**[®]
(natalizumab)

Suggested diagnostic algorithm for TYASABRI-treated patients experiencing new neurological symptoms suggestive of non-MS-related disease



Note: TYASABRI dosing should only be restarted when the diagnosis of PML is excluded, if necessary, by repeating clinical, MRI, and CSF assessment if clinical suspicion of PML remains.

CSF assessment for presence of JCV DNA should be performed using a highly sensitive quantitative real-time PCR assay with a limit of quantification (LOQ) of at least 50 copies/mL.

For more information, please call Biogen Medical Information at 1-800-456-2255.

Please see accompanying full Prescribing Information, including Boxed Warning.

Action steps if PML is suspected

1 SUSPEND DOSING

TYSABRI dosing should be suspended **immediately** in all cases in which PML is suspected.

2 MRI assessment

If the clinical presentation is suggestive of PML, further investigation should include brain MRI evaluation as soon as possible.

3 CSF assessment

If MRI evaluation reveals lesions suspicious for PML (see [Table 2 on page 9](#)), a lumbar puncture with evaluation of CSF for the detection of JCV-DNA should be undertaken with a highly sensitive quantitative real-time PCR assay.

4 Repeat testing

If clinical suspicion of PML remains despite a negative evaluation, then MRI and CSF assessments should be repeated to exclude a diagnosis of PML.

A definitive diagnosis of PML is made by evaluating clinical and MRI findings plus the identification of JCV in the CNS.

- There is no prevention, FDA-approved treatment, or cure for PML. Rapid recognition of PML and early discontinuation of TYSABRI are key interventions
- PLEX (see [page 10](#)) may be considered as a means to accelerate the clearance of TYSABRI
- Healthcare providers should promptly report serious adverse events to Biogen at [1-800-456-2255](tel:1-800-456-2255)
 - Biogen can provide additional resources, including suggested next steps


Please see accompanying full Prescribing Information, including Boxed Warning.

TYSABRI[®]
(natalizumab)

MRI assessment

- Although there are no pathognomonic findings that differentiate PML from MS, a brain MRI scan that includes fluid-attenuated inversion recovery (FLAIR) and T1- and T2-weighted sequences, with and without gadolinium (Gd), should be performed to assess patients with neurological changes suggestive of PML (see [Table 1 on page 4](#))
- Comparison with a baseline scan may assist with interpretation of the findings on the new MRI. See [Figure 1](#) and [Table 2](#) for differences in lesion characteristics that may help differentiate between PML and MS

Figure 1. MRI presentation features of PML



Adapted from Weber T. *Neurol Clin.* 2008;26(3):833–854. Used with permission.

Please see accompanying full Prescribing Information, including Boxed Warning.

Table 2. MRI lesion characteristics typical of PML and MS

Characteristic MS Lesions		PML Lesions
Location	Periventricular perpendicular to ventricles (Dawson's fingers), deep white matter, isolated U fibers, cerebellum and spinal cord	<ul style="list-style-type: none"> ➤ Subcortical WM in parietal, occipital or frontal lobes ➤ May involve precentral or postcentral gyrus (motor/sensory cortex) or insular region ➤ Follows WM tracks. Can cross the corpus callosum to contralateral hemisphere (butterfly pattern) or extend through internal capsule ➤ Rarely brainstem or cerebellar WM ➤ No spinal cord involvement
Appearance	Well defined borders	<ul style="list-style-type: none"> ➤ Infiltrating, ill-defined, confluent WM lesions which can be multifocal
Mass effect	Large lesions can have a mass effect	<ul style="list-style-type: none"> ➤ Rare even in large lesions
FLAIR	Flair = T2	<ul style="list-style-type: none"> ➤ Flair more sensitive for detection of PML lesions in subcortical location
T1W pre-contrast	Isotense or mildly hypointense to Grey matter	<ul style="list-style-type: none"> ➤ Isointense with progressive hypointensity
T1 post contrast	Homogeneous or ring-enhancement – resolves in 1-2 months	<ul style="list-style-type: none"> ➤ Patchy, punctate or linear

Adapted from Yousry TA et al. *N Engl J Med.* 2006;354(9):924-933.



Please see accompanying full Prescribing Information, including Boxed Warning.

JCV DNA testing to confirm diagnosis

- Plasma assessment
 - Presence of JCV DNA in plasma has not been correlated with the development of PML
 - Plasma JCV DNA test positivity is highly variable, so the sensitivity and predictive value of this screening method are unclear
 - Plasma JCV DNA testing is not included in the TOUCH Prescribing Program
- CSF assessment
 - The detection of JCV DNA in the CSF of a patient with clinical and MRI features suggestive of PML establishes the diagnosis of PML
 - If clinical suspicion of PML remains despite a negative CSF, testing should be repeated
 - It is recommended to test samples using a validated ultrasensitive quantitative PCR test that has a lower limit of quantification of 50 copies per mL or lower
- Brain biopsy
 - If diagnosis remains uncertain and suspicion of PML remains high, a brain biopsy may be considered to establish a definitive diagnosis

Note: TYSABRI dosing should only be resumed if the diagnosis of PML is excluded and if deemed appropriate for the ongoing treatment of MS.

PLEX

- Three sessions of plasma exchange (PLEX) over 5 to 8 days were shown to accelerate TYSABRI clearance in a study of 12 patients with MS who did not have PML, although in the majority of patients, α 4-integrin receptor binding remained high—a potential sign of continued inhibition of α 4-integrin–mediated leukocyte activity
- Additional plasma exchanges (up to a total of 5 over a 10-day period) may more consistently reduce TYSABRI plasma concentration and α 4-integrin receptor binding to below subtherapeutic levels
- Adverse events that may occur during PLEX include clearance of other medications and volume shifts, which have the potential to lead to hypotension or pulmonary edema
- Although plasma exchange has not been studied in TYSABRI treated patients with PML, it has been used in such patients in the postmarketing setting to remove TYSABRI more quickly from the circulation

Adapted from Khatri BO et al. *Neurology*. 2009;72(5):402-409.

Please see accompanying full Prescribing Information, including Boxed Warning.

Immune Reconstitution Inflammatory Syndrome (IRIS)

- IRIS has been reported in the majority of patients who developed PML and subsequently discontinued TYSABRI
- In almost all cases, IRIS occurred within days to several weeks after plasma exchange was used to accelerate TYSABRI clearance
- IRIS usually presents as an unanticipated clinical decline which may be rapid and severe, and may be fatal
- At the time of IRIS, MRI may show additional changes including Gd enhancement
- Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken

For the latest scientific information about our products or to report an adverse event, contact: [Biogen Medical Information](#)

Telephone: 1-800-456-2255 (8:30 AM to 8:00 PM ET)

Fax: Send Medical Information Request Form to
1-877-462-1530

Mail: Biogen Medical Information 14
Cambridge Center Cambridge, MA
02142

Web: <http://medinfo.biogen.com>

E-mail: medinfo@biogen.com

To report an adverse event, contact:

[Biogen](#)

Telephone: 1-800-456-2255



Please see accompanying full Prescribing Information, including Boxed Warning.

**Please see accompanying full Prescribing Information,
including Boxed Warning.**



Understanding PML for Gastroenterologists

This information is provided as an educational resource for healthcare providers and should be considered current as of the date listed herein. It is not intended to be a substitute for consultation and review of reference materials and medical literature pertaining to individual clinical circumstances. Healthcare providers should make all treatment decisions based on the context of the situation and their own clinical judgment.



Understanding PML for Gastroenterologists

The following information should be considered when undertaking the assessment and management of progressive multifocal leukoencephalopathy (PML) in adult patients treated with TYSABRI for moderately to severely active Crohn's disease (CD). During clinical trials for TYSABRI, 3 cases of PML were identified (2 in multiple sclerosis and 1 in Crohn's disease). Both multiple sclerosis patients were receiving concomitant immunomodulatory therapy and the Crohn's disease patient had been treated in the past with immunosuppressive therapy. In the postmarketing setting, additional cases of PML have been reported in multiple sclerosis and Crohn's disease patients who were receiving no concomitant immunomodulatory therapy.¹

About PML

PML is a demyelinating disease that attacks the central nervous system.² It is an opportunistic infection caused by the JC virus that typically occurs in patients who are immunocompromised.¹ The virus removes myelin that surrounds the nerves, and without this protection the nerves cannot transmit signals.³ There are no known interventions that can reliably prevent PML or adequately treat PML if it occurs.¹

How to Recognize PML

Typical symptoms associated with PML are diverse, progress over days to weeks, and include^{3,4}:

- Progressive weakness on one side of the body or clumsiness of limbs
- Disturbance of vision
- Changes in thinking, memory, and orientation, leading to confusion and personality changes
- Seizures

The progression of deficits usually leads to death or severe disability over weeks or months.³ Since these symptoms are very different from those of Crohn's disease, the appearance of any symptom of PML, including those listed above, should be investigated immediately.⁵ In Crohn's disease patients, a baseline brain MRI may also be helpful to distinguish pre-existent lesions from newly developed lesions, but brain lesions at baseline that could cause diagnostic difficulty while on TYSABRI therapy are uncommon.¹



Action Steps if PML Is Suspected

- TYSABRI dosing should be suspended immediately in all cases in which PML is suspected¹
- Immediate referral to a neurologist for assessment, potentially including¹:
 - A brain MRI to determine if lesions that could be due to PML are present
 - Cerebrospinal fluid evaluation for the presence of JCV DNA
- Potential cases of PML should be reported immediately to Biogen at 1-800-456-2255, or to the FDA's MedWatch reporting system at 1-800-FDA-1088, or via the MedWatch Web site at www.fda.gov/medwatch

Note: TYSABRI dosing should be restored only if the diagnosis of PML is excluded and if deemed appropriate for the ongoing treatment of CD in patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF- α , and who are not taking concomitant immunosuppressants (e.g., 6-mercaptopurine, azathioprine, or methotrexate) or concomitant inhibitors of TNF- α .

Indication

TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF- α . TYSABRI should not be used in combination with immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF- α .

Important Safety Information

WARNING: Progressive Multifocal Leukoencephalopathy (PML)

TYSABRI (natalizumab) increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI.

Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation including a gadolinium-enhanced MRI scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended.

Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program.

Important Safety Information Continued on next page



Important Safety Information (continued)

Progressive Multifocal Leukoencephalopathy (PML)

- Infection by the JC Virus (JCV) is required for the development of PML.
- Anti-JCV antibody testing should not be used to diagnose PML.
- There are no known interventions that can reliably prevent PML or that can adequately treat PML if it occurs. It is not known whether early detection of PML and discontinuation of TYSABRI will mitigate the disease.
- MRI findings may be apparent before clinical signs or symptoms suggestive of PML. Periodic monitoring for radiographic signs consistent with PML should be considered to allow for an early diagnosis of PML. Lower PML-related mortality and morbidity have been reported following TYSABRI discontinuation in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis.
- PML has been reported after discontinuation of TYSABRI in patients who did not have findings suggestive of PML at the time of discontinuation. Patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for approximately 6 months after discontinuation of TYSABRI.
- In MS patients, an MRI scan should be obtained prior to initiating therapy with TYSABRI. This MRI may be helpful in differentiating subsequent multiple sclerosis symptoms from PML.
- Three sessions of plasma exchange over 5 to 8 days were shown to accelerate TYSABRI clearance in a study of 12 patients with MS who did not have PML, although in the majority of patients, alpha-4 integrin receptor binding remained high. Adverse events that may occur during plasma exchange include clearance of other medications and volume shifts, which have the potential to lead to hypotension or pulmonary edema. Although plasma exchange has not been studied in TYSABRI-treated patients with PML, it has been used in such patients in the postmarketing setting to remove TYSABRI more quickly from the circulation.
- Anti-JCV antibody testing should not be performed during or for at least two weeks following plasma exchange due to the removal of antibodies from the serum.
- Immune reconstitution inflammatory syndrome (IRIS) has been reported in the majority of TYSABRI treated patients who developed PML and subsequently discontinued TYSABRI. In almost all cases, IRIS occurred after plasma exchange was used to eliminate circulating TYSABRI. It presents as a clinical decline in the patient's condition after TYSABRI removal (and in some cases after apparent clinical improvement) that may be rapid, can lead to serious neurological complications or death and is often associated with characteristic changes in the MRI. TYSABRI has not been associated with IRIS in patients discontinuing treatment with TYSABRI for reasons unrelated to PML. In TYSABRI-treated patients with PML, IRIS has been reported within days to several weeks after plasma exchange. Monitoring for development of IRIS and appropriate treatment of the associated inflammation should be undertaken.

Important Safety Information Continued on next page.



Contraindications

- TYSABRI is contraindicated in patients who have or have had PML.
- TYSABRI is contraindicated in patients who have had a hypersensitivity reaction to TYSABRI.

TYSABRI TOUCH Prescribing Program

- TYSABRI is available only through a restricted program under a REMS called the TOUCH® Prescribing Program because of the risk of PML.
- For prescribers and patients, the TOUCH® Prescribing Program has two components: MS TOUCH® (for patients with multiple sclerosis) and CD TOUCH® (for patients with Crohn's disease).
- Prescribers must be certified and comply with the following:
 - Review the TOUCH Prescribing Program prescriber educational materials, including the full prescribing information.
 - Educate patients on the benefits and risks of treatment with TYSABRI, ensure that patients receive the Medication Guide, and encourage them to ask questions.
 - Review, complete, and sign the Patient-Prescriber Enrollment Form.
 - Evaluate patients three months after the first infusion, six months after the first infusion, every six months thereafter and for at least six months after discontinuing TYSABRI.
 - Determine every six months whether patients should continue on treatment, and if so, authorize treatment for another six months.
 - Submit to Biogen the “TYSABRI Patient Status Report and Reauthorization Questionnaire” six months after initiating treatment and every six months thereafter.
 - Complete an “Initial Discontinuation Questionnaire” when TYSABRI is discontinued and a “6-Month Discontinuation Questionnaire,” following discontinuation of TYSABRI.
 - Report cases of PML, hospitalizations due to opportunistic infections, and deaths to Biogen at 1-800-456-2255 and to the Food and Drug Administration’s MedWatch Program at 1-800-FDA-1088 as soon as possible.
- Patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient-Prescriber Enrollment Form.
- Pharmacies and infusion centers must be specially certified to dispense or infuse TYSABRI.

Herpes Encephalitis and Meningitis

- TYSABRI increases the risk of developing encephalitis and meningitis caused by herpes simplex and varicella zoster viruses.
- Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting in multiple sclerosis patients receiving TYSABRI.
- The duration of treatment with TYSABRI prior to onset ranged from a few months to several years.

Important Safety Information Continued on next page.



- Monitor patients receiving TYSABRI for signs and symptoms of meningitis and encephalitis. If herpes encephalitis or meningitis occurs, TYSABRI should be discontinued, and appropriate treatment for herpes encephalitis/meningitis should be administered.

Hepatotoxicity

- Clinically significant liver injury, including acute liver failure requiring transplant, has been reported in patients treated with TYSABRI in the postmarketing setting. In some patients, liver injury recurred upon rechallenge, providing evidence that TYSABRI caused the injury.
- Signs of liver injury, including markedly elevated serum hepatic enzymes and elevated total bilirubin, occurred as early as six days after the first dose; signs of liver injury have also been reported for the first time after multiple doses.
- In some patients, liver injury recurred upon rechallenge, providing evidence that TYSABRI caused the injury.
- The combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that may lead to death or the need for a liver transplant in some patients.
- TYSABRI should be discontinued in patients with jaundice or other evidence of significant liver injury (e.g., laboratory evidence).

Hypersensitivity/Antibody Formation

- Hypersensitivity reactions have occurred in patients receiving TYSABRI, including serious systemic reactions (e.g., anaphylaxis) which occurred at an incidence of <1%.
- Reactions usually occur within 2 hours of the start of the infusion. Symptoms associated with these reactions can include urticaria, dizziness, fever, rash, rigors, pruritus, nausea, flushing, hypotension, dyspnea, and chest pain. Generally, these reactions are associated with antibodies to TYSABRI.
- If a hypersensitivity reaction occurs, discontinue administration of TYSABRI, and initiate appropriate therapy. Patients who experience a hypersensitivity reaction should not be re-treated with TYSABRI.
- Hypersensitivity reactions were more frequent in patients with antibodies to TYSABRI compared with patients who did not develop antibodies to TYSABRI in both MS and CD studies.
- Patients who receive TYSABRI for a short exposure (1 to 2 infusions) followed by an extended period without treatment are at higher risk of developing anti-natalizumab antibodies and/or hypersensitivity reactions on re-exposure, compared to patients who received regularly scheduled treatment.

Important Safety Information Continued on next page.



Immunosuppression/Infections

- The immune system effects of TYSABRI may increase the risk for infections.
- In Study MS1, certain types of infections, including pneumonias and urinary tract infections (including serious cases), gastroenteritis, vaginal infections, tooth infections, tonsillitis, and herpes infections, occurred more often in TYSABRI-treated patients than in placebo-treated patients. One opportunistic infection, a cryptosporidial gastroenteritis with a prolonged course, was observed in a patient who received TYSABRI in Study MS1.
- In Studies MS1 and MS2, an increase in infections was seen in patients concurrently receiving short courses of corticosteroids. However, the increase in infections in TYSABRI-treated patients who received steroids was similar to the increase in placebo-treated patients who received steroids
- Concurrent use of antineoplastic, immunosuppressant, or immunomodulating agents may further increase the risk of infections over the risk observed with use of TYSABRI alone. The safety and efficacy of TYSABRI in combination with antineoplastic, immunosuppressant, or immunomodulating agents have not been established.
- In Studies MS1 and MS2, the rate of any type of infection was approximately 1.5 per patient-year in both TYSABRI-treated patients and placebo-treated patients.
- In Study MS1, the incidence of serious infections was approximately 3% in TYSABRI-treated patients and in placebo-treated patients. Most patients did not interrupt treatment with TYSABRI during infections.
- In postmarketing experience, serious herpes infections have occurred.

Laboratory Test Abnormalities

- In clinical trials, TYSABRI was observed to induce increases in circulating lymphocytes, monocytes, eosinophils, basophils, and nucleated red blood cells. Observed changes persisted during TYSABRI exposure, but were reversible, returning to baseline levels usually within 16 weeks after the last dose. Elevations of neutrophils were not observed. TYSABRI induces mild decreases in hemoglobin levels (mean decrease of 0.6 g/dL) that are frequently transient.

Adverse Reactions

- The most common adverse reactions reported at an incidence of $\geq 10\%$ with TYSABRI and $\geq 2\%$ difference with placebo were headache (38% vs 33%), fatigue (27% vs 21%), infusion reactions (24% vs 18%), urinary tract infections (21% vs 17%), arthralgia (19% vs 14%), depression (19% vs 16%), pain in extremity (16% vs 14%), rash (12% vs 9%), gastroenteritis (11% vs 9%), and vaginitis* (10% vs 6%).

*Percentage based on female patients only.

- The most frequently reported serious adverse reactions in Study MS1 were infections (3.2% vs 2.6% placebo), including urinary tract infection (0.8% vs 0.3%) and pneumonia (0.6% vs 0%), acute hypersensitivity reactions (1.1% vs 0.3%, including anaphylaxis/anaphylactoid reaction [0.8% vs 0%]), depression (1.0% vs 1.0%, including suicidal ideation or attempt [0.6% vs 0.3%]), and cholelithiasis (1.0% vs 0.3%).
- Based on animal data, TYSABRI may cause fetal harm. TYSABRI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.



References:

1. TYSABRI prescribing information. Cambridge, MA: Biogen. 2. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. *N Engl J Med*. 2006;354:924-933. 3. Data on file. Cambridge, MA: Biogen. 4. Project Inform. Progressive multifocal leukoencephalopathy (PML). Available at: <http://www.projectinform.org/info/pml/index.shtml>. Accessed February 14, 2008. 5. What is Crohn's Disease? Crohn's & Colitis Foundation of America. <http://www.cdfa.org/what-are-crohns-and-colitis/what-is-crohns-disease/?referrer=https://www.google.com/>. Accessed June 24, 2016.

Please see accompanying full Prescribing Information, including Boxed Warning.

➤ TOUCH On-Line Login

➤ How do I enroll in the TOUCH Prescribing Program?

➤ TOUCH Prescribing Program Resources

➤ Learn more about TYSABRI

➤ Prescribing Information

➤ Patient Medication Guide

➤ Patient Medication Guide - Spanish

➤ Important Safety Information

TYSABRI® (natalizumab) is available only through the TOUCH Prescribing Program, which stands for TYSABRI Outreach: Unified Commitment to Health.

The TOUCH Prescribing Program is a restricted distribution program focused on safety and developed with the help of the Food and Drug Administration (FDA):

- Only prescribers and patients enrolled in the TOUCH Prescribing Program can prescribe and receive TYSABRI
- Only certain pharmacies and infusion sites authorized by the TOUCH Prescribing Program can dispense and infuse TYSABRI

The TOUCH Prescribing Program is designed to:

- Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
- Warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised.
- Promote early diagnosis of PML and timely discontinuation of TYSABRI in the event of suspected PML.

TOUCH On-Line is a web-based tool designed to assist TOUCH Prescribing Program participants in fulfilling their TOUCH Prescribing Program Requirements.

Not a TOUCH On-Line user?

To learn more about becoming a TOUCH On-Line user, call a TYSABRI Support Specialist at Biogen:
1-800-456-2255 Monday-Friday,
8:30 AM to 8:00 PM (ET)

TOUCH On-Line Login

TOUCH On-Line Username

Password

Please note that the password is case sensitive.

My password is not working, please e-mail me my password - [click here](#)

Login

Having trouble logging in?

Check with your Site Administrator or call us toll free:
1-800-456-2255, Monday through Friday, 8:30 AM to 8:00 PM (ET)

> TOUCH On-Line Login

> How do I enroll in the TOUCH Prescribing Program?

> TOUCH Prescribing Program Resources

> Learn more about TYSABRI

> Prescribing Information

> Patient Medication Guide

> Patient Medication Guide - Spanish

> Important Safety Information

How do I enroll in the TOUCH Prescribing Program?

Prescribers, infusion sites, certified pharmacies associated with infusion sites and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense or receive TYSABRI.

- **Prescribers:** The first step in enrolling in the TOUCH Prescribing Program is receiving educational materials provided by Biogen.
 - Requirements include:
 - Review the TYSABRI Patient Medication Guide with each patient and discuss the risks and benefits of starting therapy.
 - Review, complete, and submit a Prescriber/Patient Enrollment Form for each patient to acknowledge the therapy discussion and the TOUCH Prescribing Program requirements, and document the patient's consent to enroll in the program.
 - Review the Pre-Infusion Patient Checklist to make sure each patient understands the questions that will be asked prior to every infusion.
 - Evaluate the patient 3 months after the first infusion, 6 months after the first infusion, at least 6 months thereafter for as long as the patient receives TYSABRI, and for 6 months after TYSABRI has been discontinued.
 - Determine every 6 months whether a patient should continue on TYSABRI and if so, authorize treatment every 6 months.
- **Infusion Sites:** An infusion site must participate in a mandatory training program provided by a Biogen representative and complete an Infusion Site Enrollment Form documenting the site agrees to abide by the requirements of the TOUCH Prescribing Program.
 - Requirements prior to each infusion include:
 - Administer TYSABRI only to patients who are currently authorized in the TOUCH Prescribing Program. Patient authorization must be confirmed.
 - Provide each patient a copy of the TYSABRI Patient Medication Guide.
 - Complete a TYSABRI Pre-infusion Patient Checklist. The Pre-infusion Patient Checklist must be submitted to Biogen within 1 business day of the patient visit.
- **Certified Pharmacies** associated with infusion sites: A certified pharmacy must participate in a mandatory training program provided by a Biogen representative and complete a Certified Pharmacy Enrollment Form documenting the certified pharmacy agrees to abide by the requirements of the TOUCH Prescribing Program.
 - Dispense TYSABRI only to authorized infusion sites.

To learn more about enrolling in the TOUCH Prescribing Program, contact a TYSABRI Support Specialist at Biogen, call toll free: 1-800-456-2255 Monday-Friday, 8:30 AM to 8:00 PM (ET).

TOUCH Prescribing Program Resources

> TOUCH On-Line Login

> How do I enroll in the TOUCH Prescribing Program?

> **TOUCH Prescribing Program Resources**

> Learn more about TYSABRI

> Prescribing Information

> Patient Medication Guide

> Patient Medication Guide - Spanish

> Important Safety Information

There are several resources available to assist in educating healthcare providers, and thus patients, of the known risks and potential benefits of TYSABRI treatment. Distribution of TOUCH Prescribing Program forms is controlled and available only from Biogen directly. The educational materials below are available for your convenience.

Educational Tools

- **TOUCH Prescribing Program Overview**
 - This material provides an overview of the TOUCH Prescribing Program requirements and important participant responsibilities.
 - [TOUCH Prescribing Program Overview](#)
- **TOUCH Prescribing Program Educational Slide Set**
 - Presentation to provide education necessary to execute TOUCH Prescribing Program, intended for prescribers, infusion sites, and certified pharmacies.
 - [TOUCH Prescribing Program Educational Slide Set](#)
- **Diagnosing PML (progressive multifocal leukoencephalopathy)**
 - Helpful Information for Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI is a resource for Neurology specialists treating TYSABRI patients. Key topics included in this tool are the importance of careful evaluation of any new or recurrent symptoms, differentiating between the signs and symptoms typical of MS and PML, PML diagnostic algorithm incorporating MRI and CSF assessment, and action steps if PML is suspected.
 - [Helpful Information for the Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI](#)
 - Understanding PML for Gastroenterologists material is a resource for Gastroenterologists, Internists, or other non-Neurology specialists treating TYSABRI patients. Key topics included in this tool are the characteristics of PML, guidance on recognizing PML in the context of Crohn's disease, and action steps if PML is suspected.
 - [Understanding PML for Gastroenterologists](#)

To learn more about enrolling in the TOUCH Prescribing Program, contact a TYSABRI Support Specialist at Biogen, call toll free: 1-800-456-2255 Monday-Friday, 8:30 AM to 8:00 PM (ET).

Change Prescriber Authorization

By Facsimile

PRESCRIBER AUTHORIZATION REQUESTED

Date:	<Current_Date>	Patient Enrollment Number:	<Alt_ID>
New Prescriber:	<Phys_First_Name> <Phys_Last_Name>	Patient Name:	<Pat_First_Name> <Pat_Last_Name>
Address:	<MD_Address>	Patient DOB:	<Pat_DOB>
	<MD_City>, <MD_State> <MD_Zip>	Patient Enrollment Period:	Pat Auth Begin through <Pat Auth End>
Phone:	<MD_Phone>	Infusion Site:	
Fax:	<MD_Fax>	Infusion Site Address:	
Prescriber DEA:		Prescriber State License Number:	

Our records indicate that <Pat_First_Name> <Pat_Last_Name> will continue his/her TYSABRI (natalizumab) therapy under your care. If you agree to accept this patient, please sign this form and fax it to Biogen at 1-800-840-1278.

If you do not accept this patient or have questions about the TOUCH[®] Prescribing Program Requirements, please call the TOUCH Prescribing Program at 1-800-456-2255. We are available Monday through Friday.

I accept <Pat_First_Name> <Pat_Last_Name> under my care for TYSABRI (natalizumab) treatment.

<u>Prescription for TYSABRI</u>	
Dose: TYSABRI [®] (natalizumab) 300 mg	Dispense: 1 vial Refills: <u>12</u> Directions: IV infusion per Prescribing Information every 4 weeks
I authorize Biogen as my designated agent and on behalf of my patient to (1) use the information on this form to continue the enrollment of the above-named patient in the TOUCH Prescribing Program, (2) forward the prescription by fax or by another mode of delivery to a pharmacy, if applicable, and (3) coordinate delivery of TYSABRI on behalf of the above named patient.	

Prescriber Signature

Date

FAX this signed form to 1-800-840-1278

For full Prescribing Information including Boxed Warning, please see www.TYSABRI.com

TYSABRI 12-Week Questionnaire for Crohn's Disease

Please submit this form to:
Biogen
www.touchprogram.com
Fax: 1-800-840-1278

<Date>

<Prescriber Name>

<Prescriber Address>

<MD Number>

Re: <Patient Name>

Patient Enrollment Number: <Patient TOUCH ID>

Patient date of birth: <MM/DD/YYYY>

Dear <Prescriber Name>,

Our records indicate that it has been 12 weeks since <Patient Name> received his or her first dose of TYSABRI. The Prescribing Information states that if a patient with Crohn's disease has not experienced a therapeutic benefit by 12 weeks of induction of therapy she/he should be discontinued from TYSABRI treatment.

This questionnaire is necessary to fulfill the tracking requirements of the TOUCH[®] Prescribing Program for Crohn's disease patients treated with TYSABRI. You may also be contacted for additional information in response to answers provided on this form.

Submit the completed evaluation to Biogen via TOUCH On-Line (www.touchprogram.com) OR fax (1-800-840-1278) and place one copy in the patient's record.

Please answer **Yes** or **No** to the following questions:

1. Has this patient experienced a therapeutic benefit within 12 weeks after starting TYSABRI treatment?

Yes

No*

*TYSABRI should be discontinued if the patient has not experienced a therapeutic benefit by 12 weeks of induction therapy with TYSABRI.

2. Will the patient continue on TYSABRI?

Yes

No*

*If you answer No, Biogen will contact the patient and the infusion site to **STOP TYSABRI TREATMENT**. The patient will not be eligible to receive TYSABRI treatment, and you will receive a discontinuation questionnaire to complete for this patient.

If you have questions, or if you need additional information, please call 1-800-456-2255.

TOUCH Certified Prescriber or Delegate Signature: _____ **Date:** _____

(If applicable) **Print TOUCH Certified Prescriber or Delegate Name:** _____

Please Note: A TOUCH certified prescriber or delegate may complete and submit this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

For full Prescribing Information, including Boxed Warning, please see www.TYSABRI.com.

TYSABRI Patient Status Report and Reauthorization Questionnaire—MS

Please submit this form to:
 Biogen
 www.touchprogram.com
 Fax: 1-800-840-1278

<Date>
 <Prescriber Name>
 <Prescriber Address>
 <MD Number>

Re: <Patient Name>
 Patient Enrollment Number: <Patient TOUCH ID>
 Patient date of birth: <DOB>
 Authorization expiration date: <MM/DD/YYYY>

Dear <MD Name>,
 Our records indicate that <Patient Name>'s authorization to receive TYSABRI will expire on <MM/DD/YYYY> and he/she will no longer be able to receive TYSABRI. Please submit the completed form to Biogen via TOUCH On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) by <expiration date> and place a copy in the patient's record.

A Is the patient still under <MD name>'s care?
 Yes No/I don't know
 If No, please provide name and phone number for new prescriber, if available _____

H Is the patient currently receiving or has the patient received any IMMUNOMODULATORY or IMMUNOSUPPRESSANT products in the previous 6 months?
 Yes No

B Is the patient alive?
 Yes No
 Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have not reported to Biogen:

If Yes, please indicate the type of therapy and number of months of use.

C **PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)**
 Yes No or Under investigation

	Months of Use in Last 6 Months					
	1	2	3	4	5	6
AVONEX [®]	1	2	3	4	5	6
Betaseron [®]	1	2	3	4	5	6
Copaxone [®]	1	2	3	4	5	6
Rebif [®]	1	2	3	4	5	6
Extavia [®]	1	2	3	4	5	6
Gilenva [®]	1	2	3	4	5	6
Aubagio [®]	1	2	3	4	5	6
PLEGRIDY [®]	1	2	3	4	5	6
TECFIDERA [®]	1	2	3	4	5	6
LEMTRADA [®]	1	2	3	4	5	6
ZINBRYTA [™]	1	2	3	4	5	6
Azathioprine	1	2	3	4	5	6
Methotrexate	1	2	3	4	5	6
Mitoxantrone	1	2	3	4	5	6
Mycophenolate	1	2	3	4	5	6
Cyclophosphamide	1	2	3	4	5	6
Chronic systemic steroids	1	2	3	4	5	6
Other immunomodulatory or immunosuppressant therapy	1	2	3	4	5	6

D **OPPORTUNISTIC INFECTION*** for which they have been hospitalized
 Yes No or Under investigation

E **MALIGNANCY**
 Yes No or Under investigation

F Since <last authorization>, has the patient been tested for the presence of anti-JCV antibodies?
 Yes Not performed
 If performed, test result:
 Positive Negative Pending

I If the patient is still under <MD name>'s care **DO YOU AUTHORIZE the continuation of TYSABRI treatment for the next 6 months for the patient?**
 Yes No
 If you answer No, Biogen will contact the patient and the infusion site to STOP TYSABRI TREATMENT. The patient will not be eligible to receive TYSABRI treatment, and you will receive final questionnaire for this patient in 6 months.

G Is the patient currently receiving or has the patient received intermittent courses of steroids for the treatment of MS relapse in the previous 6 months?
 Yes No
 If Yes, please circle the number of courses received. 1 2 3 4 5 6 >6

*OPPORTUNISTIC INFECTION is defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, pneumocystis carinii pneumonia, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

TOUCH Certified Prescriber or Delegate Signature: _____ **Date:** _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete and submit this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com



All other trademarks are the marks of their respective owners.



TYSABRI Patient Status Report and Reauthorization Questionnaire—Crohn's Disease

Please submit this form to:
 Biogen
 www.touchprogram.com
 Fax: 1-800-840-1278

<Date>
 <Prescriber Name>
 <Prescriber Address>
 <MD Number>

Re: <Patient Name>
 Patient Enrollment Number: <Patient TOUCH ID>
 Patient date of birth: <DOB>
 Authorization expiration date: <MM/DD/YYYY>

Dear <MD Name>,

Our records indicate that <Patient Name>'s authorization to receive TYSABRI will expire on <MM/DD/YYYY> and he/she will no longer be able to receive TYSABRI. Please submit the completed form to Biogen via TOUCH On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) and place a copy in the patient's record.

A Is the patient still under <MD name>'s care?
 Yes No/I don't know
 If No, please provide name and phone number for new prescriber, if available _____

B Is the patient alive?
 Yes No

Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have not reported to Biogen:

C PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
 Yes No or Under investigation

D OPPORTUNISTIC INFECTION* for which they have been hospitalized
 Yes No or Under investigation

E MALIGNANCY
 Yes No or Under investigation

F Since <last authorization>, has the patient been tested for the presence of anti-JCV antibodies?
 Yes Not performed
 If performed, test result:
 Positive Negative Pending

G Is the patient currently receiving or has the patient received systemic steroids for the treatment of Crohn's flare in the previous 6 months?
 Yes No
 If Yes, please indicate the number of months of use:
 1 2 3 4 5 6

H Within the past year, and since starting TYSABRI, has the patient received greater than 6 consecutive months of systemic steroids for the treatment of Crohn's disease?
 Yes No

I Is the patient currently receiving or has the patient received any **IMMUNOMODULATORY, or IMMUNOSUPPRESSANT THERAPIES**, in the previous 6 months?
 Yes No
 If Yes, please indicate the type of therapy and the number of months of use.

	Months of Use in Last 6 Months					
	1	2	3	4	5	6
Remicade®						
Humira®						
Azathioprine or Mercaptopurine or Thioguanine						
Vedolizumab (Entyvio®)						
Methotrexate						
Cimzia®						
Other immunomodulatory or immunosuppressant therapy						

†Not including aminosalicylates.

J If the patient is still under <MD name>'s care **DO YOU AUTHORIZE the continuation of TYSABRI treatment** for the next 6 months for the patient?
 Yes No
 If you answer No, Biogen will contact the patient and the infusion site to **STOP TYSABRI TREATMENT**. The patient will not be eligible to receive TYSABRI treatment, and you will receive a final questionnaire for this patient in 6 months.

***OPPORTUNISTIC INFECTION** is defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, *pneumocystis carinii* pneumonia, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

TOUCH Certified Prescriber or Delegate Signature: _____ **Date:** _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete and submit this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. The questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Forum signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com



All other trademarks are the marks of their respective owners.



Prescriber name: _____
First MI Last

Prescriber address: _____
City State ZIP

Patient: _____ Patient Enrollment Number: _____
First name MI Last name

Patient date of birth (MM/DD/YYYY): ____/____/____

- This TYSABRI Patient Discontinuation Questionnaire is necessary to fulfill the tracking requirements of the TOUCH® Prescribing Program for all patients treated with TYSABRI. You may also be contacted for additional information in response to answers provided on this form.
 - Submit the completed TYSABRI Patient Discontinuation Questionnaire to Biogen via TOUCH On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) and place one copy in the patient's record.
- This form is mandatory for all discontinued patients.

A Is the patient still under <MD name>'s care?
 Yes No/I don't know
If No, please provide name and phone number for new prescriber, if available _____

B Is the patient alive?
 Yes No

Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have *not* reported to Biogen:

C PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
 Yes No or Under investigation

D OPPORTUNISTIC INFECTION* for which they have been hospitalized
 Yes No or Under investigation

*OPPORTUNISTIC INFECTION is defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, *pneumocystis carinii* pneumonia, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

E MALIGNANCY
 Yes No or Under investigation

F Since <last authorization>, has the patient been tested for the presence of anti-JCV antibodies?
 Yes Not performed
If performed, test result:
 Positive Negative Pending

TOUCH Certified Prescriber or Delegate Signature: _____ Date: _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com

**Initial Discontinuation
 Questionnaire—Crohn's Disease**

<Date>

<Prescriber Name>

<Prescriber Address>

<MD Number>

Dear <MD Name>,

Re: <Patient Name>

Patient Enrollment Number: <Patient TOUCH ID>

Patient date of birth: <DOB>

Our records indicate that <Patient Name> received a final dose of TYSABRI on <MM/DD/YYYY>.

- This Initial Discontinuation Questionnaire is necessary to fulfill the tracking requirements of the TOUCH[®] Prescribing Program for Crohn's disease patients treated with TYSABRI. You may also be contacted for additional information in response to answers provided on this form.
- Submit the completed Initial Discontinuation Questionnaire to Biogen via TOUCH On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) and place one copy in the patient's record. This form is mandatory for all discontinued patients.

A Is the patient still under <MD name>'s care?
 Yes No/I don't know
 If No, please provide name and phone number for new prescriber, if available _____

B Is the patient alive?
 Yes No
 Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have *not* reported to Biogen:

C PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
 Yes No or Under investigation

D OPPORTUNISTIC INFECTION* for which they have been hospitalized
 Yes No or Under investigation

E MALIGNANCY
 Yes No or Under investigation

F Since <last authorization>, has the patient been tested for the presence of anti-JCV antibodies?
 Yes Not Performed
 If performed, test result:
 Positive Negative Pending

G Since <MM/DD/YYYY> is the patient currently receiving or has the patient received systemic steroids for the treatment of a Crohn's flare?
 Yes No
 If Yes, please circle the number of months of use:
 1 2 3 4 5 6

H Within the past year, and since starting TYSABRI, has the patient received greater than 6 consecutive months of systemic steroids for the treatment of Crohn's disease?
 Yes No

I Since <MM/DD/YYYY> is the patient currently receiving or has the patient received any **IMMUNOMODULATORY**, or **IMMUNOSUPPRESSANT THERAPIES**?
 Yes No
 If Yes, please indicate the type of therapy and the number of months of use.

	Months of Use in Last 6 Months					
	1	2	3	4	5	6
Remicade [®]						
Humira [®]						
Azathioprine or Mercaptopurine or Thioguanine						
Vedolizumab (Entyvio [®])						
Methotrexate						
Cimzia [®]						
Other immunomodulatory or immunosuppressant therapy [†]						

[†]Not including aminosalicylates.

***OPPORTUNISTIC INFECTION** is defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, *pneumocystis carinii* pneumonia, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

TOUCH Certified Prescriber or Delegate Signature: _____ **Date:** _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete this form and submit on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com



TYSABRI 6-Month Discontinuation Questionnaire—MS

Please submit this form to:
Biogen
www.touchprogram.com
Fax: 1-800-840-1278

Prescriber name: _____
First MI Last

Prescriber address: _____
City State ZIP

Patient: _____ Patient Enrollment Number: _____
First name MI Last name

Patient date of birth (MM/DD/YYYY): ____/____/____

- This TYSABRI Patient Discontinuation Questionnaire is necessary to fulfill the tracking requirements of the TOUCH® Prescribing Program for all patients treated with TYSABRI. You may also be contacted for additional information in response to answers provided on this form
- Submit the completed TYSABRI Patient Discontinuation Questionnaire to Biogen via TOUCH® On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) and place one copy in the patient's record. This form is mandatory for all discontinued patients

A Is the patient still under <MD name>'s care?

Yes No/I don't know

If No, please provide name and phone number for new prescriber, if available _____

B Is the patient alive?

Yes No

Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have *not* reported to Biogen:

C PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Yes No or Under investigation

D OPPORTUNISTIC INFECTION* for which they have been hospitalized

Yes No or Under investigation

E MALIGNANCY

Yes No or Under investigation

***OPPORTUNISTIC INFECTIONS** defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, *pneumocystis carinii pneumonia*, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

F Since <last authorization>, has the patient been tested for the presence of anti-JCV antibodies?

Yes Not performed

If performed, test result:

Positive Negative Pending

TOUCH Certified Prescriber or Delegate Signature: _____ **Date:** _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete and submit this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the TOUCH Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com

TYSABRI

6-Month Discontinuation Questionnaire—Crohn's Disease

<Date>

<Prescriber Name>
<Prescriber Address>
<MD Number>

Re: <Patient Name>
Patient Enrollment Number: <Patient TOUCH ID>
Patient date of birth: <MM/DD/YYYY>

Dear <Prescriber Name>,

Our records indicate that <Patient Name> received a final dose of TYSABRI on <MM/DD/YYYY>.

- This Discontinuation Questionnaire is necessary to fulfill the tracking requirements of the TOUCH[®] Prescribing Program for Crohn's disease patients treated with TYSABRI. You may also be contacted for additional information in response to answers provided on this form.
- Submit the completed 6-Month Discontinuation Questionnaire to Biogen via TOUCH On-Line (www.touchprogram.com) **OR** fax (1-800-840-1278) and place a copy in the patient's record. This form is mandatory for all discontinued patients.

A Is the patient still under <Prescriber Name>'s care?

Yes No/I don't know

If **No**, please provide contact information for new prescriber, if available.

Name and phone of new prescriber: _____

B Is the patient alive?

Yes No

Since starting TYSABRI therapy has the patient been diagnosed with any of the following that you have **not** reported to Biogen:

C PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)

Yes No or Under investigation

D OPPORTUNISTIC INFECTION* for which they have been hospitalized

Yes No or Under investigation

E MALIGNANCY

Yes No or Under investigation

*OPPORTUNISTIC INFECTION is defined as an infection due to an organism that generally does not cause disease, or causes only mild or self-limited disease in people with normally functioning immune systems, but causes more significant disease in people with impaired immunity. These infections are frequently severe, prolonged, or disseminated. Examples include esophageal candidiasis, systemic fungal infections, pneumocystis carinii pneumonia, mycobacterial infections (including pulmonary and extra-pulmonary tuberculosis), chronic intestinal cryptosporidiosis, and disseminated viral infections (such as disseminated herpes or cytomegalovirus infections).

TOUCH Certified Prescriber or Delegate Signature: _____ Date: _____

(If applicable) Print TOUCH Certified Prescriber or Delegate Name: _____

Please Note: A TOUCH certified prescriber or delegate may complete and submit this form on behalf of the certified Prescriber of record. The certified TOUCH Prescriber of record is responsible for compliance with the TOUCH Prescribing Program requirements, including monitoring, evaluation, and management of each patient under his/her care. This questionnaire will be used consistent with the Touch Prescriber/Patient Enrollment Form signed by you and your patient with HIPAA and applicable privacy rules. If you have questions, or if you need additional information, please call 1-800-456-2255.

For full Prescribing Information, including Boxed Warning, please see www.TYSABRI.com.

The TOUCH® Prescribing Program was developed as part of the Biogen commitment to patient safety. Only authorized certified pharmacies may dispense to authorized infusion sites. A certified pharmacy may become authorized after it has taken part in compulsory training conducted by Biogen and faxed a completed Enrollment Form to Biogen. Upon receipt of this Enrollment Form, Biogen will fax and mail an Authorization Confirmation Letter to provide your Pharmacy Authorization Number and confirm your Shipping Address. This letter will also provide you with the Site Authorization Numbers of any of your associated infusion sites that have been authorized to infuse TYSABRI.

*A certified pharmacy is located within a hospital, group practice, or infusion site and is associated with an infusion site. Retail pharmacies and wholesalers are excluded from holding inventory and dispensing TYSABRI.

Certified Pharmacy Shipping Address

Please note that this is the ONLY address to which TYSABRI will be shipped.

Name of Certified Pharmacy			Contact name		
Address 1			NCPDP		
Address 2			Title/position		
City	State	ZIP	Telephone	<input type="text"/>	<input type="text"/>
			Fax	<input type="text"/>	<input type="text"/>

Associated Infusion Site Name

Please list all potential infusion sites that your pharmacy supports. If you need additional space, please attach a separate page.

<p>1</p> <p>Name of Infusion Site</p> <p>Contact name</p> <p>Address</p> <p>City State ZIP</p>	<p>2</p> <p>Name of Infusion Site</p> <p>Contact name</p> <p>Address</p> <p>City State ZIP</p>
<p>3</p> <p>Name of Infusion Site</p> <p>Contact name</p> <p>Address</p> <p>City State ZIP</p>	<p>4</p> <p>Name of Infusion Site</p> <p>Contact name</p> <p>Address</p> <p>City State ZIP</p>

I confirm that the above information is correct. I understand that by signing this form this pharmacy agrees to dispense TYSABRI only to associated infusion sites that have been authorized according to the TOUCH Prescribing Program.

Certified Pharmacy Acknowledgment

- The pharmacy has received training and educational materials on the TOUCH Prescribing Program for use in the following indication(s):
 MS CD (check all that apply)
- Certified pharmacies may dispense TYSABRI only to authorized infusion sites
- I understand that, per the requirements of the TOUCH Prescribing Program, this certified pharmacy's compliance may be reviewed by the Food and Drug Administration (FDA), and/or audited by Biogen, and/or a third party designated by Biogen.
- I understand that noncompliance with the requirements of the TOUCH Prescribing Program may result in my pharmacy no longer being enrolled and termination of our participation in the program

Responsible party acknowledgment: _____ Date: _____
 Name: _____ Title: _____

Please see accompanying full Prescribing Information.



Infusion Site Enrollment Form

The TOUCH® Prescribing Program was developed as part of the Biogen commitment to patient safety. Only authorized infusion sites may receive shipments of and infuse TYSABRI. An infusion site may become authorized only after it has taken part in compulsory training conducted by Biogen and faxed a completed Enrollment Form to Biogen. Upon receipt of this Enrollment Form, Biogen will fax and mail an authorization confirmation letter to provide your Site Authorization Number and confirm your Shipping Address.

Infusion Site Address (address where patient is infused)

Name of Infusion Site _____			Contact name _____		
Address1 _____			Telephone <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>		
Address2 _____			Fax <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>		
City _____	State _____	ZIP _____			

Method of acquiring TYSABRI

1 Infusion site will acquire TYSABRI directly. If YES, check all that apply: Buy/Bill Assignment of Benefits/Specialty Pharmacy

OR

2 Infusion site will acquire through a certified pharmacy.*

*A certified pharmacy is located within a hospital, group practice, or infusion site and is associated with an infusion site. Retail pharmacies and wholesalers are excluded from holding inventory and dispensing TYSABRI.

Shipping Address (address to which drug will be shipped)

Check here if address is same as above. Please note that this is the ONLY address to which TYSABRI will be shipped.

Name of Infusion Site or Certified Pharmacy _____			Contact name _____		
Address 1 _____			Telephone <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>		
Address 2 _____			Fax <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>		
City _____	State _____	ZIP _____			

Infusion Site Acknowledgment

- The infusion site has received training and educational materials on the TOUCH Prescribing Program for use in the following indication(s): MS CD (check all that apply)
- I understand that TYSABRI will be administered only to patients who are currently authorized in the TOUCH Prescribing Program. Patient authorization must be confirmed *prior to each infusion* by:
 - For TOUCH On-Line infusion sites: Patient Authorization Status must be "Authorized" or
 - For paper-based infusion sites: Receipt of current Notice of Patient Authorization and verification that no Notice of Patient Discontinuation is on file
- I understand that each patient will receive a copy of the TYSABRI Patient Medication Guide *prior to each infusion*
- I understand that a TYSABRI Pre-infusion Patient Checklist must be completed *prior to each infusion*. The Pre-infusion Patient Checklist must be submitted to Biogen within 1 business day of the patient visit regardless of whether or not the patient received the infusion by:
 - For paper-based infusion sites: sending a copy of the completed Pre-infusion Patient Checklist to Biogen. A copy must also be placed in the patient's medical record
 - For TOUCH On-Line infusion sites: the infusion nurse can read, complete and submit the Pre-Infusion Patient Checklist directly in TOUCH On-Line
- I understand that, per the requirements of the TOUCH Prescribing Program, this infusion site's compliance may be reviewed by the Food and Drug Administration (FDA), and/or audited by Biogen and/or a third party designated by Biogen
- I understand that noncompliance with the requirements of the TOUCH Prescribing Program will result in de-enrollment of the infusion site and termination of the authorization to infuse TYSABRI.

Responsible party acknowledgment: _____ Date: _____

Name: _____ Title: _____

Please see full Prescribing Information, including Boxed Warning, at www.TYSABRI.com

